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Abstract
After severe peripheral nerve injury, such as transection, regeneration has been observed over
variable gap lengths with the use of the nerve stump entubulation method. Following
entubulation, exudate from transected nerve stumps coagulates into a fibrin matrix within the
entubulated space by the end of the first week. Over the following four weeks, two distinct
groups of cells migrate into the fibrin-filled gap. The first group consists of fibroblasts which
differentiate into the myofibroblast phenotype, forming concentric, force-applying layers
collectively known as the contractile capsule around the periphery of newly forming tissue. The
second group of cells includes undifferentiated fibroblasts, Schwann cells, and endothelial cells
which migrate into the fibrin core preceding axon elongation and synthesis of new nerve tissue.
The pressure cuff hypothesis states that the forces applied by myofibroblasts in the contractile
capsule deform new tissue and disrupt regeneration. Previous efforts to model the pressure cuff
hypothesis have described the release of exudate and the effect of forces applied by cells on the
deformation of the regenerate. However, the effects of the conduit chosen for entubulation and
the kinetics of early processes have not yet been analyzed. This work aims to further describe
the pressure cuff hypothesis, emphasizing activity that occurs within the first two weeks post-
transection. A new mechanical model is presented to describe the mechanical attenuation of
myofibroblast forces by a nerve conduit, and a novel kinetic model is presented to describe the
effects of fibrin clot formation, nerve tissue formation, and contractile capsule formation on the
wound healing outcome. The results suggest that the presence of a nerve conduit acts to
attenuate the load applied to coagulated fibrin inside the gap during the early stages (< 2 weeks
post-injury) of wound healing and that the deformation of fibrin is highly dependent on the
growth rate of the capsule and the antagonistic activity between cells that synthesize new nerve
tissue and cells that form the contractile capsule. Ex vivo evidence is presented to support the
hypothesis that the properties of nerve conduits can affect capsule growth and the migration of
Schwann cells and axons into the gap. In the context of the mechanical model, these effects
result in altered mechanical states of fibrin that may affect downstream regenerative processes.
Additionally, an in vitro model that can be used to further study the effects of biomaterial
properties on capsule formation is proposed.
Thesis Supervisor: loannis V. Yannas
Title: Professor of Mechanical Engineering and Biological Engineering
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Chapter 1: Introduction and Background
In the past forty years, profound advances in bioengineering have unearthed the potential for
tissue and organ regeneration. One prominent method in this still emerging field is the use of
collagen-based scaffolds as templates for regeneration, which has been successful in regenerating
skin [6], peripheral nerves [7], and the conjunctiva [8]. Severe injuries to the peripheral nervous
system (PNS) in particular are devastating, as they can result in partial or total paralysis and loss
of sensory functions. Consequently, the field of tissue and organ regeneration has the potential
to significantly improve the quality of life for victims of peripheral nerve injuries.
Although collagen-based scaffolds of well-characterized and finely tuned mechanical properties
result in successful regeneration of skin, peripheral nerves, and the conjunctiva, the mechanism
by which they do so is not fully understood. Fetal wound healing is known to be regenerative
prior to the third trimester of gestation, at which point the response becomes non-regenerative, or
marked by repair through contraction and scar formation [4]. The adult response of wound
surface area reduction through contraction is a result of the activity of cells which express a-
smooth muscle actin (a-SMA), most often myofibroblasts. The sequence of events during the
transition from fetal to adult wound healing remain unknown. A prevalent theory supported by
experimental data suggests that the quality of regeneration in the adult mammal is determined by
the extent to which the normal adult healing response-that is, contraction and scar formation-
is inhibited [4, 6, 9].
Many regeneration attempts in the peripheral nervous system have involved connecting fully
severed nerve stumps by filled or unfilled conduits of various materials, a procedure known as
post-transection entubulation. Entubulation of nerve stumps can restore a large percentage of
functionality in nerve stump separation gaps of up to 15 mm in the rat sciatic nerve [10, 11].
Despite the experimental and clinical success of the entubulation method, many questions remain
unanswered regarding the mechanisms involved in regeneration versus scar formation and the
specific effects of the chosen entubulation material and/or filling on the development and quality
of the regenerate. After transection and entubulation, a fibrin clot forms in the cavity between
nerve stumps from the exudate released by the injured tissue [12-14]. After 3 days, fibroblasts
are the first cells to migrate into the chamber between nerve stumps using the formed clot as a
13
framework, but are followed by Schwann cells shortly thereafter [15]. Some fibroblasts
differentiate into the myofibroblast phenotype, forming concentric, force-applying layers
collectively known as the contractile capsule around the periphery of newly forming tissue.
Other fibroblasts remain undifferentiated and migrate into the core of the fibrin clot along with
Schwann cells and endothelial cells, preceding axon elongation and synthesis of new nerve
tissue. It has been described previously that regeneration may depend on the relationship
between processes that control the activities of these two cell groups; in other words,
regeneration is favored if nerve tissue forms at a faster rate than the contractile capsule [16].
1.1 Anatomy of the Peripheral Nervous System
The central and peripheral nervous systems work together to transmit signals from the brain to
the rest of the body and vice versa. The central nervous system (CNS) contains the brain and
spinal cord, while the peripheral nervous system (PNS) is composed of all other nerves
throughout the body. A single peripheral nerve is composed of both neuronal and nonneuronal
tissues, the former including neurons and axons and the latter including components of the extra-
cellular matrix (ECM) and local cells [17, 18].
The neuron is the most basic unit of the PNS. As a complete structure, the neuron allows the
body to transmit signals over both short and long distances. It is composed of the soma (which
contains the cell nucleus), dendrites, an axon, axon terminals, and sometimes a myelin sheath
synthesized by Schwann cells (Figure 1.1). The dendrites receive and transmit signals from the
immediate surroundings to the soma. The longest dendrite is known as the axon, and the axon
terminals are located at its distal end from the soma. Axon terminals receive signals from
locations large distances away from the soma and transmit them via the axon. Sometimes, a
sheet of protein created by Schwann cells called the myelin sheath wraps around the axon in
order to increase the speed of signal transmission [19].
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Figure 1.1. Neuron cell structure.
In peripheral nerves, many neurons are typically bundled together within connective tissue called
the endoneurium to form a larger structure known as a fascicle [20]. Each fascicle is wrapped by
a collagenous web-like tissue called the perineurium [21]. Peripheral nerves contain one or more
fascicles for transmission of electrical signals, which are surrounded by another loosely
organized collagenous tissue known as the epineurium [17, 21]. In normal peripheral nerves,
average observed collagen fiber diameters of these tissues are as follows: 80 nm in the
epineurium [22, 23] and 52 nm in the perineurium and endoneurium [23, 24]. Epineurial
collagen is mostly oriented along the nerve axis [21, 23, 25], while perineurial collagen forms a
"lacework" pattern around circumferential perineurial cells; endoneurial collagen forms two
layers, the outer with collagen fibers aligned along the nerve axis and the inner with collagen
forming a woven structure [21]. Nutrients are supplied to nerve structures via blood vessels that
are dispersed within the epineurium. Figure 1.2 shows a schematic of typical peripheral nerve
organization in cross-section, including the structures mentioned above.
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Figure 1.2. Schematic of a peripheral nerve in cross-section [3].
1.2 Irreversible Injury
All organs in the adult mammal are subject to irreversible injury, or an injury which results in a
permanent loss of normal organ function and/or structure [4]. Before the third trimester, the
mammalian fetus heals by spontaneous regeneration, or complete restoration of organ structure
and function following irreversible injury [26, 27]. Into the third trimester, the adult mammal
begins to heal by another spontaneous process (repair) which does not result in regeneration but
in contraction of the defect and formation of a scar lacking the normal structure and function of
the original tissue(s) [28]. This transition from regeneration to repair suggests that, although
severe injuries to organs of the adult mammal typically result in repair and scar formation, it may
indeed be possible to revert back to the fetal response of regeneration given the proper
conditions.
1.2.1 Human Response to Irreversible Injury
No tissue or organ in the adult human is able to regenerate spontaneously. The liver is often
cited as an organ capable of regeneration, but this is not entirely true. The liver actually exhibits
hyperplasia, a phenomenon in which liver mass to body size ratio is maintained [29]. This
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healing response does not, however, keep the normal lobed structure of the organ [30]. Other
organs and tissues, such as blood vessels [31, 32], muscle [33, 34], the spinal cord [35], and
cartilage [36] exhibit typical non-regenerative behavior in which both function and structure are
compromised.
Researchers have traditionally called the result of the spontaneous adult healing response "scar."
Scar (also called fibrosis, elastosis, fibrous capsule, and referred to by other names in specific
organs) identifies the reparative fibrous tissue that forms after injury. It is predominantly
composed of connective tissue in all organs, but there appears to be no universal composition. In
the dermal scar of the guinea pig following a full-thickness skin wound, the tissue is
characterized by low vascularity and collagen fibers on the order of 10 gm; these fibers are
arranged preferentially in the plane of the tissue, a pattern not observed in normal skin [37].
Although use of the term "scar" in skin may be a familiar one, it is more challenging to connect
the term to injuries of other organs in the body. Interestingly, in the rat sciatic nerve following
transection, the proximal and distal nerve stumps become poorly vascularized masses of
nonmyelinated axons and fibrous tissue known as neuromas, which are strikingly similar to
traditional dermal scar [38]. This finding seems to imply that, although the organs of the adult
mammal are distinctly different from one another, they exhibit similar wound healing outcomes.
In the next section, a paradigm known as the tissue triad is introduced and used to further
investigate the similar wound healing response observed in various organs of the adult mammal.
1.2.2 The Tissue Triad
Because all organs and tissues are susceptible to irreversible injury resulting in loss of function
and/or structure, it is useful to develop a framework that enables comparisons to be made
between various tissues and organs at the most basic level. The structure of many organs can be
described by what is known as the tissue triad [4], or a layered organization of three tissue types:
epithelia, basement membrane, and stroma [17, 39]. Epithelium, the cellular, non-vascularized
tissue layer of any organ, is capable of spontaneous regeneration in the adult mammal without
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intervention. Stroma, the tissue layer composed of extracellular matrix (ECM) and blood
vessels, is not capable of spontaneous regeneration [4].
In the skin, for instance, the epidermis is the epithelial tissue and the dermis is the stroma; the
two are attached to one another by an acellular basement membrane, which is capable of
spontaneous regeneration after injury as long as the dermis remains intact (Figure 1.1, left) [4].
In peripheral nerves, there is evidence that each axon is surrounded by tissues which behave
similarly to the epidermis and dermis in skin. The myelin sheath formed by Schwann cells
seems to behave like the epithelia, while the endoneurium is non-regenerative like the stroma [4,
40]. As in the skin, the two are separated by a basement membrane (Figure 1.1, right). In both
organs, the epithelia and the basement membrane have been shown to regenerate spontaneously,
but the stroma heals by repair [4, 9, 41-43]. Employment of the tissue triad paradigm suggests
that regeneration of any organ can occur spontaneously so long as the stroma remains intact but
will be replaced by repair if the stroma is compromised. This implies that, if one can
successfully regenerate the stroma of an organ, spontaneous (though imperfect) regeneration of
the entire organ can be induced [4].
Figure 1.3. Tissue triad (epithelia, basement membrane, and stroma) in human skin (left) and
peripheral nerves (right) [4].
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1.2.3 Methods Available to Replace an Irreversibly Injured Organ
The most drastic clinical method used to replace an irreversibly injured organ is transplantation,
in which a partial or full organ is removed from a donor and placed into another host. One of the
challenges associated with this treatment is host rejection. Immunosuppressants are often
administered to the host in an effort to prevent this adverse response but carry the serious risk of
increased vulnerability to infection [44].
Under certain conditions, some organs, including skin [45] and peripheral nerves [46-48], can be
harvested from another location in the host and used as autografts to replace an irreversibly
injured organ. This treatment prevents the possibility of host rejection but leaves a donor site
which can be prone to post-operative complications. Implantation of a permanent prosthesis
eliminates both donor site morbidity and host rejection. However, permanent prostheses are
typically made from ceramics, metals, and/or polymers that can potentially elicit a severe
biological response in the short- or long-term due to biological incompatibility.
Another approach available to replace an irreversibly injured organ is in vitro synthesis, which
has been used extensively to produce keratinocyte sheets that can be transplanted into skin
wounds to generate an epidermis over relatively large surface areas in which spontaneous
regeneration of the epithelial tissue may not occur [49]. Within the past 20 years, use of stem
cells for organ replacement has also been explored both in vitro and in vivo. While the potential
is vast, the inability to control differentiation with accuracy and specificity is a huge remaining
hurdle [50].
The final method available for replacement of an irreversibly injured organ is use of an
extracellular matrix (ECM) analog. This method has resulted in successful regeneration of
several organs and will be covered in more detail in section 1.3.3.
1.3 Contraction, a-SMA, and Cytokines in Adult Spontaneous Repair
As previously discussed, early fetal wound healing results in regeneration while adult wound
healing results in scar formation [4]. Another possible outcome of the adult spontaneous wound
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healing response is contraction, a phenomenon in which local cells actively and independently
apply contractile forces on the order of 1-10 nanoNewtons per cell [51, 52] to decrease wound
surface area. The process of contraction during wound healing is mediated by cells that express
a-smooth muscle actin (a-SMA), most commonly myofibroblasts [4, 53-55]. Although cells
expressing a-SMA are ubiquitously present in healthy, uninjured tissue (including the
perineurium of peripheral nerves [56]), their quantity increases dramatically after an injury is
introduced [4, 57, 58].
Reduction of wound surface area begins two days post-injury, but large quantities of cells
expressing a-SMA do not appear until four days after injury [59]. These observations suggest
that, very early in the wound healing response, wound closure may be mediated by traction
forces as local cells migrate into the wound. However, because traction forces have traditionally
been difficult to measure with accuracy and precision, many researchers treat the wound healing
response as one mediated completely by contractile cells expressing a-SMA.
1.3.1 The Defect Closure Rule
Assuming that an anatomically well-defined wound (see [4] for a discussion of this topic) is
created and examined in the initial state directly after an injury is induced and in the final state
when the defect is fully closed, surface area changes in the defect over time can be monitored
and quantified. Since it is believed that the closure of any defect can occur through only three
possible processes (contraction [C], scar formation [S], and regeneration [R]) [4, 28], each
process can represent the wound healing outcome as a percentage of wound closure by
C + S + R = 100 1.1
which is known as the defect closure rule. During adult spontaneous repair, contraction and scar
formation dominate the response. Thus, in order for regeneration to occur, Equation 1.1 implies
that contraction and scar formation must be reduced. Indeed, evidence suggests that the
percentage of defect closure that is regenerative in the skin of the guinea pig [6, 9, 60-63] and in
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sciatic nerves of the rat [5, 7, 64] can be maximized by disrupting the contraction of the wound
and by preventing scar formation [4].
1.3.2 Cytokines
Cytokines are signaling molecules that can increase or decrease various cell activities. In the
wound healing response in particular, transforming growth factor-P 1 (TGF-pl ) has been found to
upregulate expression of a-SMA and induce differentiation of fibroblasts into the myofibroblast
phenotype [65]. Similarly, transforming growth factor-p2 (TGF-p2) has also been linked to an
upregulation of contraction and scar formation. In vivo studies have reported that a reduction in
TGF- PlI and TGF- P2 expression during late fetal wound healing leads to decreased scarring and
that TGF- Pl and TGF- P2 are expressed in lower quantities in early fetuses that exhibit
spontaneous regeneration [66, 67]. In contrast, transforming growth factor-p3 (TGF-p3) has
been associated with decreased scarring and is found in more abundance in early regenerative
fetuses than in adults [66, 67]. Although specific wound healing pathway changes as a result of
modifications in the levels of these cytokines are unknown, the data collectively suggest that
cytokines may have a significant role in the wound healing outcome of regeneration versus
contraction and scar formation.
1.3.3 The Extracellular Matrix (ECM) and its Analogs
There is significant evidence that cells are able to sense and respond to the environment in which
they are placed [68]. An in vitro study in which nerve explants were placed in contact with
collagen-GAG scaffolds of different mechanical properties demonstrated that the contractile
behavior of nerve explant cells is significantly affected by the pore size and level of crosslinking
in the scaffold [69].
In the biological environment, cells are surrounded and supported by the extracellular matrix
(ECM). The ECM is the structural component of tissues in which cells thrive; it is composed of
collagen, elastin, fibronectin, laminin, proteoglycans, and glycosaminoglycans, all of which work
cohesively as insoluble regulators of cell behavior [70-73]. The nature of the relationship
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between cells and their surrounding ECM leads to a feedback loop in which ECM properties
affect cell behavior and cells modify the properties of the ECM, which leads to modifications in
cell behavior and so on [74]. Little is understood about the details of this feedback loop, which
is further complicated through constant remodeling of the ECM by collagenases and matrix
metalloproteases (MMPs) [75-77]. The majority of researchers have studied these activities
through cell interactions with gels [78-80] or two-dimensional substrates composed of ECM
proteins [68], but these are poor analogs to the three-dimensional structure of the ECM in the
biological environment [81].
A three-dimensional, porous scaffold is considered an analog of the ECM if it is able to regulate
cell behavior and provide structural integrity in similar ways as native ECM [1]. It is not fully
understood which individual properties (e.g. composition, pore size, stiffness, degradation rate,
etc.) of the ECM or its analogs are responsible for controlling particular behaviors of cells [6].
Even so, use of collagen-based ECM analogs with carefully controlled properties following
severe organ injury has resulted in regeneration of typically non-regenerative tissues (a
comprehensive review can be found in [4]). It is hypothesized that the ECM analogs used in
these successful regeneration attempts may interfere with the contractile response of cells during
wound healing and thus prevent scar formation while inducing regeneration [4, 57].
In studies of peripheral nerves, the nerve regeneration template (NRT) has been used as an ECM
analog to fill conduits made often of silicone or collagen [7, 11, 82, 83]. A study of the
effectiveness of several ECM analogs in regenerating nerves across a 10 mm gap concluded that
the best structural properties of a chondroitin 6-sulfate copolymer used to fill collagen tubes
include an average pore size of 5 pm oriented along the axis of the nerve trunk, a 95% pore
volume fraction, and a half-life of four weeks [84, 85]. These properties, which appear to have a
significant effect on the outcome of wound healing, dictate the surface area and therefore the
quantity and density of ligands available to local cells in addition to the length of time that the
ECM analog is present in the wound site.
In the PNS, use of a collagen nerve guide facilitates regeneration across gaps of 15 mm or above,
while standard empty silicone tubes become ineffective in inducing regeneration for gap lengths
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greater than 10 mm [86]. Other experimental variations, such as semipermeable and permeable
tubes [87-9 1], saline filled tubes [92], ECM protein-supplemented tubes/fillings [93-100],
Schwann cell-enriched fillings [101-104], addition of growth factors [105-111], addition of
plasma [112], and even nerve tissue fillings [113] have also been studied and result in various
qualities of regeneration. Clearly, these studies suggest that PNS regeneration is highly
dependent on the materials chosen for entubulation.
Harley, et al. developed a process by which to homogenize and characterize the fabrication of
collagen-based matrices by lyophilization (freeze-drying) using cellular solids theory [1, 114,
115]. The details of the lyophilization process have been described previously [1, 4, 114].
Briefly, a slurry of type I collagen is mixed with acetic acid and optional glycosaminoglycans
(GAGs). The slurry is then frozen at a constant cooling rate into the desired macroscopic
geometry, resulting in formation of ice crystals throughout. Formed ice crystals are later
sublimated, leaving pores in their place. The final freezing temperature is a parameter that can
be used to control scaffold pore size by modifying the size of formed ice crystals [114]. For the
purpose of this work, type I bovine collagen (0.5 wt%, Integra LifeSciences, Plainsboro, NJ) was
used for scaffold fabrication (see Appendix A for detailed protocols).
After freeze-drying, the stiffness and degradation rate of collagen-GAG scaffolds can be
controlled by various crosslinking methods. Dehydrothermal (DHT) crosslinking is performed
by placing scaffolds in a heated vacuum oven to form covalent bonds between collagen fibers.
There are also chemical crosslinking processes (e.g. EDAC-a solution of 1 -ethyl-3-(3-
dimethylaminopropyl)carbodiimide) which involve application of a chemical solution to the
scaffold for a specified period of time. DHT crosslinking is generally preferred for regenerative
applications, as it is believed to better preserve the microstructure (viz. ligands) of the proteins
comprising the scaffold and is a more gentle and gradual method of crosslinking.
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1.4 Background Literature References to the Kinetics of Peripheral Nerve
Regeneration
After entubulation of transected nerve stumps, exudate containing plasma begins to flow out of
severed nerve stumps at a rate of approximately 1 tL per hour [14, 92]. This exudate contains
the protein fibrinogen and the protease thrombin [12-14]. Thrombin cleaves fibrinogen to create
fibrin, a fibrous protein which then becomes crosslinked to local fibronectin also present in the
exudate [116]. Individual fibers of fibrin aggregate to form a macroscopic network known as a
fibrin clot, which serves as a framework for cells to migrate into the gap created by entubulation.
Properties of typical fibrin clots are discussed in more detail in section 1.4.1. Cells cannot attach
to fibrin alone, so crosslinked fibronectin is required to promote adhesion and migration of cells
participating in wound healing [80, 117].
The first cells to migrate into the gap along the nerve axis from both the proximal and distal
nerve stumps are fibroblasts followed closely by Schwann cells [13, 116]. Some fibroblasts
migrate along the periphery of the fibrin clot and become contractile; others migrate through the
fibrin core along with Schwann cells and endothelial cells, preceding subsequent synthesis of
new nerve tissue and elongation of axons into the gap. Many kinetics studies of peripheral nerve
regeneration utilize histological nerve cross-sections at various locations and time points along
the nerve axis to detect when cells first migrate to a location or when structures first appear. For
example, Williams, et al. have used this method to estimate that fibroblasts and Schwann cells
migrate across an entubulated gap in the rat sciatic nerve at a rate of approximately 2.5 mm/wk,
while axons elongate at a rate of 1 mm/day [116]. Other investigators have studied the kinetics
of nerve regeneration by monitoring parameters which indicate the functionality of the nerve
(e.g. conduction velocity and latency [84, 118, 119]) until they reach a constant value.
Soon after transection, Wallerian degeneration occurs in the distal nerve stump. In this process,
axons and myelin sheaths degrade and local Schwann cells and macrophages infiltrate the area to
remove debris [120]. Schwann cells, fibroblasts, and endothelial cells begin to migrate into the
gap from nerve stumps around 3 days post-transection [116]. During migration, Schwann cells
leave behind tubes in the fibrin clot called Bands of Btingner that can subsequently help guide
elongating axons toward reconnection [18, 35]. By two weeks post-injury, Schwann cells and
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fibroblasts can be seen along the majority of a gap created by a 10 mm silicone nerve guide, and
nonmyelinated axons can be seen near both the proximal and distal nerve stumps [116]. By three
weeks, Schwann cells and fibroblasts can be seen throughout the entire gap of a 10 mm silicone
nerve guide, and both myelinated and nonmyelinated axons can be observed [116]. For a period
of time after injury which depends on the gap length between nerve stumps, axons must elongate
through the gap from the proximal end of the nerve toward the distal end to restore a pathway for
signal transmission. The time during which the axons are elongating but have not yet made a
functional connection is known as the "silent" period; for a 10 mm gap in the rat sciatic nerve
which is entubulated by a collagen-GAG scaffold, the "silent" period is about eight weeks [84].
In the absence of a nerve conduit, the exudate and resulting fibrin clot is not contained,
preventing guided migration of cells and axons from the proximal and distal nerve stumps. This
is a major reason why large gaps do not result in spontaneous regeneration without entubulation.
It has also been proposed that the absence of entubulation allows exogenous fibroblasts to disrupt
fibrin clotting and downstream interactions between fibrin and Schwann cells that promote the
elongation and reconnection of axons [121].
It has also been noted that many contractile myofibroblasts align circumferentially as early as
one week post-transection around nerves treated with conduits of both silicone and collagen-
GAG matrices (empty, filled with GAG-free collagen, or filled with collagen-GAG), remaining
until 30 and even 60 weeks later [5, 83, 94]. Myofibroblasts in silicone tubes form a thick 10-20
cell layer capsule approximately 40-120 ptm thick that surrounds the nerve trunk; a much thinner
capsule is observed around nerves treated by collagen tubes with the proper mechanical
properties [5, 86, 112]. Evidence seems to suggest that the chosen nerve guide material
significantly affects the number of contractile cell layers, which may positively correlate with the
magnitude of contractile forces produced by cells of the capsule and negatively correlate with
regenerate quality [2, 5, 16].
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1.4.1 The Mechanical Properties of Fibrin and Fibronectin
Fibrin is formed when the precursor protein fibrinogen is cleaved by the protease thrombin to
form a twisted structure called a protofibril [122, 123]. Protofibrils grow and form larger,
twisted fibers through lateral aggregation [123] which branch out to form three-dimensional
fibrin clots [124].
Within the first week post-injury, a fibrin clot containing approximately 5-10% fibronectin forms
within the entubulated space between nerve stumps and serves as a temporary framework for
migration of local cells [12-14]. In order for cells to attach to fibrin, crosslinking of fibronectin
(present in the blood plasma and deposited by cells, particularly fibroblasts [13]) to the fibrin clot
is required; this is particularly important in wound healing to promote adhesion and migration of
fibroblasts and Schwann cells participating in the wound healing response [80, 117]. A fibrin
polymer can be observed in the post-transection entubulation chamber as soon as 3 days after
entubulation, but it takes approximately one week before the entire length of the channel is filled
with fibrin [112, 113, 116].
Fibrin clot structure and fiber diameter is affected greatly by nerve conduit fillings. Saline
fillings, for example, result in fibrin clots of lower density and smaller fiber diameter than clots
observed in unfilled conduits [92]. Further, there is additional evidence that these changes to
fibrin structure can affect the migration speed of both contractile cells along the periphery of the
fibrin clot and of fibroblasts and Schwann cells into the fibrin core [92, 112, 125, 126].
Very little is known about the mechanical properties of the fibrin comprising in vivo clots,
particularly for sciatic nerve regenerates. This makes it somewhat difficult to discern the
structural implications of fibrin in peripheral nerve regeneration [124]. It is estimated that only
0.25% of a formed fibrin clot is solid, while the rest is liquid [124]. This significant liquid
component imparts the observed viscoelastic behavior of fibrin clots. Clots composed of thick
fibers as opposed to thinner fibers remain more deformed for short loading times (<1 hour) while
the reverse is true for clots composed mostly of thinner fibers [124, 127, 128]. Interestingly,
under special conditions, fibrin can be considered elastic. This occurs for small strains of fine-
fiber clots imposed over a time scale of 1-100 seconds [129]. There is some evidence to suggest
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that the elasticity of fibrin arises from fiber bending [125, 130], but this hypothesis has yet to be
validated.
Factor XIIIa (activated fibrin-stabilizing factor, or FSF [131]) is an enzyme in the plasma that
crosslinks fibrin clots by forming amide cross links between molecules of fibrin [132]. Because
the fibrin precursor fibrinogen is derived from animal sources, the concentration of Factor XIIIa
varies in many commercial products [133, 134]. As a result, there may be some variance in
Young's moduli reported in the literature for fibrin clots produced in vitro depending on the
commercial product used and the batch of animals from which it was derived. In general,
fibrinogen concentration has been found to affect the Young's modulus of fibrin more
significantly than thrombin concentration, resulting in an overall fibrin stiffness range of 58 Pa
(2 mg/ml fibrinogen, 2 U/ml thrombin) to 4 kPa (>50 mg/ml fibrinogen, >50 U/ml thrombin) in
vitro [128]. The fibrinogen and thrombin composition of fibrin gels has also been shown to
affect fibroblast migration [135].
It should be stressed that the majority of current studies conducted to determine the mechanical
properties of fibrin are based on tests of fibrin clots created in vitro from purified proteins, which
of course do not accurately represent in vivo clots. Absent additional proteins and regulators in
vitro likely affect the aggregation patterns of fibrin and, in turn, its mechanical properties [124,
136]. These limitations may induce errors which should not be ignored.
1.4.2 Possible Mechanisms of Peripheral Nerve Regeneration
Peripheral nerve regeneration is currently described by three possible mechanisms. The first
mechanism states that contractile cells deform the regenerating organ early in the wound healing
response and irreversibly damage the tissue structure [4]. The second states that contraction
creates a stress field in the regenerate that sends signals to cells which cascade and result in poor
regeneration; the third is based on the idea that the presence of synthesized scar physically
obstructs the formation of new nerve tissue [16].
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The pressure cuff hypothesis describes how the presence and accumulation of the myofibroblast
capsule governs the quality of regeneration in peripheral nerves [4]. Brau developed the first
model of this theory in which the regenerate is in contact with the contractile cell capsule but
mechanically isolated from the entubulating nerve guide [137]. An extension of this model by
Zhang, et al. used fluid mechanics principles to describe how formation of a fibrin matrix from
exudate may determine the maximum gap length between transected nerve stumps which will
still result in successful regeneration [138].
Both of these models are severely limited, as they neglect the nerve conduit used for entubulation
as well as the kinetics of early stage fibrin, nerve tissue, and capsule formation. Quantitative
mechanical modeling of early stage (1-2 weeks post-transection) entubulated peripheral nerves
remains difficult due to limited information regarding regeneration kinetics and the dynamic
mechanical properties of local tissues during wound healing. However, modeling of both spatial
and temporal changes in early stage wound healing is critical to obtain further insight into the
mechanisms involved in peripheral nerve regeneration.
This work is unique in its emphasis on the peripheral nerve wound healing response within the
first two weeks post-transection. Three new mechanical models are presented in this thesis to
describe the effects of contractile cell forces on the wound healing response of transected
peripheral nerves. The first model investigates the mechanical effect of a nerve conduit on the
wound healing response. It describes how the presence of a conduit attenuates the load applied
to tissue inside the gap by cells of the contractile cell capsule, resulting in decreased deformation
of the fibrin clot relative to analyses in which the conduit is absent (i.e. the Brau model). The
second model incorporates into the preceding model the distinct mechanical properties of the
contractile cell capsule, aiming to more accurately represent the histology of entubulated nerves
and determine the mechanical effect of the capsule itself on entubulated regeneration. The
results of this model suggest that, particularly in the late stages of wound healing, the capsule
further attenuates contractile forces applied by contractile cells to entubulated tissue. Finally, a
novel model is presented that integrates the mechanics of the first two models with the kinetics
of fibrin, nerve tissue, and capsule formation during the first 2 weeks post-transection. This
kinetic model suggests that capsule and nerve tissue formation are competing processes;
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furthermore, the relative activity between the two processes has a potentially significant effect on
the outcome of wound healing.
Experimental results from two studies are also presented in order to assess the effects of nerve
guide properties on the formation of both new nerve tissue and the contractile capsule. In the
first study, ex vivo nerve images from post-transection entubulation studies conducted by Soller
et al. [16] are used to monitor and quantify Schwann cell migration, axon elongation, and capsule
formation as a function of time and location. The collagen-based nerve conduits studied in this
thesis differ only in the method used for crosslinking (dehydrothermal versus chemical), and
result in regenerates of very different quality at 9 weeks post-transection [2].
Additionally, an in vitro model that can be used to further study the effects of biomaterial
properties on capsule formation is proposed. This model emulates entubulated wound healing by
seeding cells at a fibrin-biomaterial interface analogous to the location of contractile cells in vivo
between the fibrin clot and nerve conduit. Differentiation of fibroblasts at this interface into the
contractile phenotype can be monitored at various time points to determine the potential effect of
biomaterials on formation of the capsule during wound healing. Each of these contributions
attempts to aid in understanding of the mechanical, biological, and chemical effects of the nerve
conduit on the elementary processes of regeneration. Ultimately, increased knowledge in these
areas will enhance future optimization of biomaterials used to induce regeneration of peripheral
nerves and other organs.
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Chapter 2: Mechanical Modeling of the Pressure Cuff Hypothesis
Transected peripheral nerve stumps separated by a long enough gap heal spontaneously by
formation of a neuroma in vivo. The healing response resulting from transection followed by
entubulation of nerve stumps depends on conduit properties (material, pore size, degradation
rate) and the length of the gap between nerve stumps [139]. Large gaps entubulated by non-
bioactive materials (e.g. silicone elastomer) often result in the formation of a neuroma, while
smaller gap lengths entubulated by silicone elastomer have been shown to form new nerve tissue
in the rat sciatic nerve (albeit of lower quality than the original). Highly porous collagen-based
conduits with carefully adjusted structural features have been used to successfully regenerate the
rat sciatic nerve over larger gaps than silicone conduits and with a regenerate of superior quality
[5, 16, 139, 140]. A quantitative description of the process by which this may occur is presented
in this chapter.
There is evidence that wound healing after entubulation of transected nerve stumps with a
bioactive, collagen-based conduit follows a different process than spontaneous wound healing
(without entubulation). This complex, multi-step process begins immediately after injury as the
gap between entubulated nerve stumps fills with exudate released from the injured stumps. The
exudate forms a fibrin clot within the first week post-transection [112, 116]. Then, cells that
become contractile migrate into the gap from the stumps at the interface between the fibrin clot
and the inner surface of the conduit while endoneurial cells (fibroblasts, Schwann cells, and
endothelial cells) migrate into the core of the fibrin clot [116, 141]. Finally, axons attempt to
elongate through the gap [18]. If they are able to successfully reconnect the proximal and distal
nerve stumps, signal conduction is restored to some extent.
One goal in this work is to model the effects of conduit mechanical properties on the elementary
processes of peripheral nerve regeneration. The pressure cuff hypothesis emphasizes that forces
applied by contractile cells mechanically deform new tissue forming in the gap and impede
regeneration [4]. The contractile cells responsible for this effect are myofibroblasts, which
aggregate to form concentric layers (collectively known as the contractile cell capsule) between
the clot and the nerve conduit. At 9 weeks post-transection, there is evidence of an inverse
correlation between the thickness of the contractile cell capsule and the quality of the resulting
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regenerate [16]. This suggests that contractile forces applied by myofibroblasts may directly
affect peripheral nerve regeneration.
This chapter presents several models that describe the effects of contractile cell forces on
entubulated regeneration. First, an existing model of the pressure cuff hypothesis is discussed.
This model describes the healing process of the transected nerve in the absence of a nerve
conduit. Then, three new mechanical models are described. The first model investigates the
effect of nerve conduit properties on the wound healing response. The second model
incorporates into the preceding model the contractile cell capsule and its distinct mechanical
properties, aiming to more accurately represent the histology and determine the effect of the
capsule itself on entubulated regeneration. Finally, this chapter presents a novel model that
integrates the mechanics of previous models with the kinetics of nerve and capsule formation.
Together, these models attempt to explain the effect of nerve conduit properties and the kinetics
of nerve tissue and capsule formation on the wound healing outcome.
2.1 Background: Existing Models
The pressure cuff hypothesis states that forces applied by myofibroblasts in the capsule are
responsible for deforming the regenerating nerve trunk and impeding regeneration [4]. This
theory is based on observations that spontaneous wound healing post-transection results in a
regenerate surrounded by a thick capsule of layered contractile cells [5, 83]; a recent study
suggests that there is an inverse relationship between the thickness of this capsule and the quality
of regeneration [16]. The first quantitative mechanical model proposed to describe the pressure
cuff hypothesis was developed by Brau [137]. The Brau model represents the nerve trunk as a
cylinder with constant cross-sectional area and the capsule as a surrounding concentric shell with
uniform thickness [137]. It is assumed that the compressive load applied by capsule cells, Umf3,
scales linearly with the capsule thickness, t, such that
amfm = Got 2.1
where c is the load applied per unit capsule thickness [137].
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Assuming no-slip between the nerve trunk and capsule and linear, elastic, and isotropic materials
(i.e. viscoelastic and poroelastic effects [137, 142] are ignored), force equilibrium requires that
the nerve trunk must balance the load applied by contractile cells. It can be shown that the
resulting radial and tangential stresses (arr, a00 ) and strains (Err, E0 ) in the nerve tissue as well
as the change in nerve radius, AR are
arr = aO = amfb 2.2
1
Err = E0 = (1 - V)amfb 2.3
E
AR = -" (1 V)Uamfb 2.4E
where E and v are Young's modulus and Poisson's ratio of the nerve trunk, ummf is the
compressive pressure applied by myofibroblasts in the capsule, and R0 is the undeformed radius
of the nerve trunk. Equations 2.1 and 2.4 show that, according to the Brau model, the thickness
of the capsule is the sole factor in determining nerve trunk deformation.
Later, Zhang, et al. used fluid mechanics principles to develop a model of early (1-2 post-injury)
wound healing after transection of peripheral nerves. This model describes how formation of a
fibrin matrix from exudate may determine the maximum gap length between transected nerve
stumps which still results in successful regeneration [143]. Both existing models have several
limitations. For one, neither model explicitly accounts for the presence of a nerve conduit.
Therefore, the Brau model is unable to describe possible mechanical effects of entubulation on
the wound healing process, and the model developed by Zhang, et al. cannot suggest how
different conduit properties may affect the potential success of regeneration. Previous studies
have suggested that biomaterial properties, including stiffness, significantly affect the quality of
in vivo regeneration [4, 16]. Consequently, it is possible that nerve conduit properties may
induce a mechanical effect on the entubulated wound healing response which differs from that-
observed in unentubulated wound healing.
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A second limitation of the Brau model lies in its attribution of nerve tissue deformation entirely
to compressive forces applied by cells in the capsule. This assumption results in inaccurate
predictions of experimental observations. For reasonable parameter values (see Table 2.1),
Equation 2.4 predicts that a 10-15 layer capsule, which has resulted in approximately 50% radial
reduction using silicone nerve conduits in vivo [113], results in a radial deformation of less than
1%:
AR = -(1 - v)uotE
2.5
A R
- = (500 kPa)-1(0.75)(40 - 400 Pa/layer)(10 - 15 layers) = 0.06 - 0.9%
RO
Therefore, the Brau model is unable to describe experimental observations on its own. When
cells that form the capsule begin to apply forces to tissue, active polymerization of fibrin from
released exudate is occurring [116]. Therefore, it is unlikely that contractile cells are applying
forces to nerve tissue and far more likely that they are compressing fibrin. Because fibrin is
more compliant than nerve tissue [128, 144], it is probable that observed significant
deformations at early time points are to the fibrin clot, not to nerve tissue as previously suggested
by Brau [137]. Therefore, an alternative mechanism is presented in this thesis in which
mechanical forces applied by contractile capsule cells do not deform nerve tissue but the former
fibrin clot. It is hypothesized that this deformation reduces the framework available for
migrating cells that later synthesize new nerve tissue, potentially disrupting downstream
regenerative processes.
Finally, both existing models neglect the effect of kinetics on the wound healing process, which
are particularly important in the early, dynamic stages of regeneration. In peripheral nerves [16]
and skin [6], it has been shown that the degradation rate of a biomaterial affects both the quality
of new tissue and the quantity of contractile cells. Additional evidence that the mechanical and
chemical properties of the nerve conduit affect the early processes of wound healing comes from
in vivo observations that collagen conduits improve axon elongation, Schwann cell elongation,
and the development of new blood vessels in regenerates compared to silicone conduits [140]. It
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is believed that an antagonistic relationship exists between myofibroblasts which form the
contractile capsule and endoneurial cells which synthesize new nerve tissue [16]. Therefore, it is
reasonable to assume that the relative kinetics associated with the activity of each cell group may
have a significant impact on the outcome of the wound healing process.
Below, three models will be presented to integrate the mechanical effect of the nerve conduit and
the kinetics of capsule/nerve formation on peripheral nerve regeneration. Before the models are
discussed in detail, estimates of critical model parameters are discussed and justified based on
relevant literature. The first model presented extends Brau's model to include the mechanical
effects of the nerve conduit. The second model also considers the mechanical properties of the
multi-layer contractile cell capsule. Finally, the third model integrates mechanics with kinetics
to describe how mechanical forces applied by cells of the contractile capsule deform the
compliant fibrin matrix which forms after injury. Together, these models of the pressure cuff
hypothesis emphasize the role of mechanics and kinetics on the early processes of peripheral
nerve wound healing.
2.2 Estimation of Modeling Parameters
The standard animal model used to study entubulated peripheral nerve regeneration involves full
transection of the rat sciatic nerve followed by entubulation of the stumps within a nerve conduit.
When the nerve is examined upon removal (typically several weeks later), there is new nerve
tissue in the gap. This new nerve tissue is surrounded by circumferentially aligned contractile
cells (the capsule). Thus, the structure can be modeled by three concentric layers of a cylinder
(from the outside): conduit, contractile cell capsule, and fibrin/nerve tissue (Figure 2.1).
This thesis considers a specific example of entubulation using a porous collagen-based scaffold
as the nerve conduit. It is desired to estimate the following modeling parameters that describe
the geometric and mechanical properties of this construct (as shown in Figure 2.1): Rt
(fibrin/nerve tissue radius), R'" = Rt + n * tm (fibrin/nerve tissue radius plus myofibroblast cell
layer thickness for n=1 to N), RS = Rt + N * tm + ts (fibrin/nerve tissue radius plus
myofibroblast capsule and scaffold thicknesses), Et (fibrin/nerve tissue stiffness), Em
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(myofibroblast capsule layer stiffness), Es (scaffold stiffness), vt (fibrin/nerve tissue Poisson's
ratio), v" (myofibroblast capsule Poisson's ratio), v5 (scaffold Poisson's ratio),
and -mn>(compressive circumferential load applied by myofibroblasts in the capsule layer).
Rt, tmts, Et, E", Es, vt, vm, and vs are estimated based on relevant literature and available data,
as shown in Table 2.1.
Et,vt E',Vm
Es., Vs
Figure 2.1. Graphic illustration of modeling parameters for the thin capsule and multi-layer
capsule models.
Table 2.1 shows that the range of fibrin/nerve tissue stiffness varies from 58 Pa to 500 kPa; in
the early stages of polymerization, the tissue is a fibrin clot with a stiffness of approximately 58
Pa [128], while healthy nerve ultimately has a stiffness of 500 kPa [144]. The full range is
included here to account for variations in tissue composition during the entire process of wound
healing. Conduit stiffness is also presented as a range from 154-1498 Pa. This is based on a
library of collagen-based scaffolds characterized by Harley [1] and later used for an in vivo rat
peripheral nerve regeneration study by Soller [2]. This library of scaffolds will hereby be
referred to as scaffolds A, B, C, D, and E, as defined in Table 2.2.
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Table 2.1. List of parameter values for the thin capsule and multi-layer capsule models.
Parameter Description Value Reference
Rt Fibrin/nerve tissue radius 0.5 mm This study
tm Myofibroblast layer thickness 5 pm Chamberlain, et al., 2000 [5]
ts Collagen scaffold thickness 0.5 mm This study
Et Fibrin/nerve tissue stiffness 58 Pa - Duong, et al., 2009 [128],
500 kPa Borschel, G.H., M.D., et al.
[144]
Em Myofibroblast layer stiffness 100 Pa Miyazaki, 2000 [145]
Es Conduit stiffness 154- Harley 2006 [1]
1498 Pa
vt Fibrin/nerve tissue Poisson's ratio 0.25 Duong, et al., 2009 [128]
vm Myofibroblast layer Poisson's ratio 1/3 Zheng and Mak, 1997 [146]
vs Conduit Poisson's ratio 0.01 Harley 2006 [1]
Table 2.2. Young's moduli of collagen scaffold library samples [1, 2].
Scaffold E' (Pa) Crosslinking
A 154 N/A
B 208 DHT 90 'C, 24 hours
C Uncharacterized DHT 90'C, 48 hours
D 225 DHT 120'C, 48 hours
E 1498 EDAC
To calculate the compressive circumferential load applied by myofibroblasts, denoted as a-mfb, it
is estimated that 1 to approximately 10 nN/cell [52, 147] can be applied by contractile
fibroblasts. The thickness of a single capsule cell layer has been observed to be approximately 5
pm [5]. Therefore, if one cell of the contractile capsule applies 1-10 nN of force, an
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infinitesimal "one-cell" approximation (Figure 2.2) can be used to calculate the compressive
circumferential load, umh (Equation 2.5).
amfb Orni - Fmfb
5 p'm
Figure 2.2. Schematic of the "one-cell" approximation used to estimate the compressive
circumferential load applied by myofibroblasts, aUm.
Implementation of the "one-cell" approximation, as shown in Figure 2.2, results in the following:
Fmm 1 - 10 nN
amff = = =40 - 400 Pa 2.6Applied Area (5 pm)2
2.3 Thin Capsule Model
The objective of the thin capsule model is to describe the mechanical effect of the nerve conduit
on healing of the entubulated peripheral nerve after transection. The mechanical model
previously developed by Brau [137] attributes the experimentally observed reduction in nerve
diameter entirely to compressive forces exerted by cells of the contractile cell capsule. It
mechanically isolates nerve tissue from the conduit and models the contractile capsule as a radial
pressure source. As discussed, this model suffers from serious limitations. Many bioactive
conduits, such as the collagen-based scaffold considered in this thesis, contain binding sites
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(ligands) to which cells can to attach and apply forces via integrins. Because cells of the
contractile capsule are in contact with the scaffold surface, they are able to apply forces to both
the scaffold and new tissue. This redistributes the forces applied by contractile cells, which in
turn affects tissue deformation.
The Brau model describes the effect of capsule cell forces on the deformation of nerve tissue, but
when cells that form the capsule (which are the first to migrate into the entubulated cavity [141]),
come into contact with tissue, fibrin polymerization is an active process. Therefore, at this early
stage of wound healing, it is more likely that contractile cells are applying forces to fibrin than to
nerve tissue. Fibrin is more compliant than nerve tissue by several orders of magnitude [128,
144], a factor that could have significant implications on modeling results. The logical first steps
to improve upon the Brau model are then i.) to include the presence of a scaffold and ii.) to
modify mechanical properties such that the tissue composition is more accurately represented by
the mechanical properties of fibrin as opposed to nerve tissue. For simplicity, the contractile cell
capsule will be modeled as infinitesimally thin in this first model. Because of this simplification,
the mechanical properties of the contractile cell capsule layer are neglected and the isolated
effects of the nerve conduit can be studied. The model developed to describe these effects is
called the thin capsule model.
2.3.1 Model Derivation
The thin capsule model describes how the mechanical properties of the nerve conduit affect the
distribution of stresses in the tissue due to forces generated by contractile cells. This is distinct
from the previous model developed by Brau [137], which does not consider the effect of the
conduit and therefore can only model the effects of nerve conduit materials that do not provide
sites for cell attachment and force application (e.g. silicone elastomer). Conversely, the thin
capsule model is more accurate in describing the mechanics of entubulation with nerve conduits
that allow cells to attach (e.g. collagen-based nerve scaffolds) and apply forces.
This model represents the tissue by a solid cylinder with linear elastic and isotropic properties.
The conduit (a collagen-based scaffold in this thesis) is represented by a hollow cylinder with
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inner diameter equal to the diameter of the tissue, also with linear elastic and isotropic properties
(Figure 2.3). Additionally, the finite thickness of the capsule (5-100 prm, depending on the
experimental setup [5, 86, 112]) is approximated as infinitesimally small for simplicity such that
the capsule is modeled as an equivalent radial compressive pressure that must be balanced by the
tissue and scaffold to satisfy equilibrium. It is assumed that the tissue and scaffold are under no-
slip conditions. Effectively, the no-slip condition means that cells of the capsule attach and
apply forces to both the scaffold and the tissue inside; the accuracy of this assumption highly
depends on the material chosen for entubulation and will be discussed later. Finally, it is
assumed that the scaffold immobilizes the proximal and distal nerve stumps such that there is no
strain in the axial (z) direction, that all deformation is axisymmetric due to symmetric geometric
and loading conditions, and that strains are small.
Tissue ,
h
Scaffold
Z
x
Figure 2.3. Schematic of the thin capsule model.
From this point, tissue and scaffold properties will be denoted by "t" and "s" superscripts,
respectively. The objective of the thin capsule model is to determine the radial stress/strain
(UrrErr), hoop stress/strain (aee/Ege), axial stress/strain (uzz/Ez), and radial deformation (ur) of
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the tissue as a function of tissue and scaffold mechanical properties and the loads applied by cells
of the contractile cell capsule using equilibrium equations and prescribed boundary conditions.
The equilibrium equations in cylindrical coordinates (r, 0, z) are
Oyrr 1 dyro + Grz +rr - GO0
+- + + =0Or r N 1z r
adrO 1 8 0 0 Ocae 2 aro+ - + + =0 2.7
ar r 0 az r
OGrz 1 OaCz O+zz +rz
Or r N az r
Due to assumptions of axisymmetric loading/deformation and plane strain, there are no shear
stresses (are = Gez = Grz = 0), reducing the equilibrium equations to
Oarr +rr - U00 
_
+ =-0Or r
- = 0 2.8
r 0
yzz = 0
az
The stress-strain relationship inside both materials can be described by Hooke's Law for an
isotropic material, or
a = C E 2.9
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E(1-v)
(1- 2v)(1 + v)
Ev
(1-2v)(1+v)
Ev
(1- 2v)(1 + v)
0
0
0
Ev
(1- 2v)(1 + v)
E(1-v)
(1- 2v)(1 + v)
Ev
(1- 2v)(1 + v)
0
0
0
Ev
(1- 2v)(1 + v)
Ev
(1- 2v)(1 + v)
E(1-v)
(1- 2v)(1 + v)
0 0 0
0 0 0
0
0 E(1+ v)
0
0
0 0
0 0
0 E(1+ v) 0
0 0 E(1+ v)
where the tissue and scaffold each have unique properties E (Young's modulus) and v (Poisson's
ratio). In cylindrical coordinates, the equations for strain are
'Our
Err - or
E-g0 - 190+--r
r O0 r
auz
- az
1 au+ 1 aur uo')
2 ar r aO r
F- z --: 1 a1 u e 1 a u z )Es = a
z 2 \. z rOO6
1 z (z
rz=2 ar
2.11
aur
+z I
Because of the assumptions of rigid ends and axisymmetric loading, uz = uO = 0; however, the
radial displacement (ur) is non-zero. Therefore, Equation 2.11 simplifies to
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-yrr 
-
Uoz
Urz
.Gre-
Err
Ezz
EOz
Erz
Ere
2.10
19ur
Err - &
Ur
E0 0 - r
Ezz = Ere = EOz = Erz = 0
Combining equations 2.10 and 2.12, the stress equations can be rewritten as
aur ur
arr = C(1 - V) + -Cv
ar r
Gu =- Cv + - C(1 - v)
,Or r
zz= (Ur
ar
90z = Grz = Gre = 0
where
EC = (1 - 2v)(1 + v)
Evaluating the stress expressions (Eq. 2.13) under equilibrium (Eq. 2.8), removing trivial
equations, multiplying by r2 , and dividing by C(1 - v) yields
r2 u" + ru' - u = 0
where u" =
a
2 Ur, u 
iU
ar 9u = Or , and u = Ur. The solution to this ordinary differential equation,
nondimensionalized with the radius of the tissue (Rt), is
Ar BRt
u(r) =- + -Rt r
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2.12
2.13
2.14
2.15
2.16
ur)C
r
Equation 2.16 shows that the full stress-strain behavior of each material can be described by two
unknown constants (A, B), resulting in a total of four constants required to fully define the thin
capsule model (A', Bt, As, Bs).
The resulting nonzero strains and stresses for each material are
BR 2
Err = A -r2 
2.17
BR 2
EseO = A + r2
BRt23 BR 2
arr = (A r2 C(1-v)+ (A+ r 2 ) Cv
BRt2 BRt2 2.18
a00 = (A+ r2 C(l-v)+ (A r2 )Cv
Yzz = 2ACv
The four constants of the thin capsule model can be calculated based on the four prescribed
boundary conditions. First, due to the assumption of axisymmetric deformation, there will be a
singularity unless Bt=O
ut(0) = 0 => Bt=0 2.19
Second, the no-slip condition between the tissue and scaffold requires that the radial
displacement at R must be equal in both materials
ut(Rt) = us(Rt) => (At) = (As + Bs) 2.20
Third, because the outer radius of the scaffold (RS) is a free surface
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Ur (R') = 0 > (As - BsR 
t2
Rs2) C'(1 - vS) + (As + B ) CsvS= 2.21
Finally, due to the application of contractile forces by myofibroblasts at the tissue-scaffold
interface (r=Rt),
atos(Rt) + age(Rt) = ame => AtCt + AsCs + BsCS(1 - 2vs) = amffi 2.22
After the constants At, B, As, and B' are determined using the boundary conditions expressed in
Equations 2.19-2.22, they are substituted into Equation 2.17 and Equation 2.18 to provide the
following expressions for the stress distributions and radial deformations in the tissue and
scaffold:
rr(r) = atO(r)= 1 Ct
2.23
at(r)= 2vttr(r)
u r (r) = ae ((r) =mfb ( Rt2
R t2)
r2 1
Tzz(r) = 2vs air(r)
ut(r) = Umfb R (1
us(r) = amfb __ (1
E R s2
2.24
2.25
2.26
2.27
- 2vs) + 1
r Rt
Rt r
where X = Rt2 (1Rs ( - 2vs)(Ct + CS) + Ct + Cs(1 - 2vs). Note that the choice to model the tissue
as a solid cylinder results in constant stress components within the tissue.
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- 2vs) )C'
- 2v')
cm Rt2
(1 -2vs) +S s
2.3.2 Results
Figure 2.4 shows the effect of tissue stiffness on tissue radial displacement, and Figure 2.5 shows
the distribution of stresses in the nerve conduit for a collagen-based scaffold crosslinked by the
dehydrothermal crosslinking process (DHT) with a Young's modulus of 225 Pa. This
corresponds to scaffold D (Table 2.2) in an in vivo scaffold library experiment (conducted by
Soller [2]), which yields a high-quality nerve regenerate.
Effect of Tissue Stiffness on Tissue Radial Displacement
(ES=225 Pa)
0.14 -
--- Et = 58 Pa
0.12- o Et = 250 Pa
0.1 - Et = 500 kPa
.- 0.08-
-- 0.06-
0.04-
0.02 -
04 0.2 0.4 0.6 0.8
r/Rt
Figure 2.4. Radial displacement in the tissue as a function of the tissue radius.
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Figure 2.5. Distribution of radial, hoop, and axial stresses in the scaffold for ES=225 Pa. This
value of the stiffness corresponds to scaffold D used in an in vivo scaffold library experiment
(conducted by Soller [2]), a nerve conduit which yields a high-quality nerve regenerate.
Figures 2.6 and 2.7 show the radial/circumferential and axial stress distributions inside the tissue
as a function of scaffold mechanical properties. Even though the stiffness of collagen-based
scaffolds is well-characterized after fabrication [114], implantation in vivo results in degradation
of the conduits which decreases scaffold stiffness and increases the stress/displacement
magnitude in the tissue. Therefore, it is necessary to consider the full range of possible scaffold
stiffnesses (Figures 2.6 and 2.7) in order to accurately describe in vivo conditions.
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Effect of Tissue and Scaffold Stiffhess on Tissue Radial Stress
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Figure 2.6. The effect of nerve conduit stiffness normalized against tissue stiffness on the
radial/hoop stress in the tissue. Scaffold A and Scaffold D ranges are provided to illustrate
potential changes due to scaffold degradation, which would reduce scaffold stiffness.
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Effect of Tissue and Scaffold Stiffness on Tissue Axial Stress
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Figure 2.7. The effect of nerve conduit stiffness normalized against tissue stiffness on the axial
stress in the tissue. Scaffold A and Scaffold D ranges are provided to illustrate potential changes
due to scaffold degradation, which would reduce scaffold stiffness.
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Figure 2.8 shows the effect of scaffold stiffness on tissue displacement for tissue stiffness values
within the range defined in Table 2.1. The results show that the stress-strain response in the
tissue (and in the scaffold) is a function not only of the forces applied by cells in the capsule but
also of the scaffold's mechanical properties.
Effect of Tissue and Scaffold Stiffness
on Maximum Tissue Radial Displacement
0.351 . . . ... . -. .. I -...
1 0 1 210 10 10
ES/Et
Figure 2.8. The effect of nerve conduit stiffness normalized against tissue stiffness on the radial
displacement in the tissue.
2.3.3 Discussion
The objective of the thin capsule model was to describe the mechanical effect of the nerve
conduit on stress distributions and radial deformations within the tissue during early stage
peripheral nerve regeneration (< 2 weeks post injury). Cells which later form the capsule begin
to migrate into the gap as early as 3 days post-transection when fibrin is entubulated within the
conduit [116, 141]. At this time point, the model suggests that the scaffold acts to attenuate the
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loads applied to the fibrin clot by cells of the capsule relative to the unentubulated case. Fibrin is
more compliant than nerve tissue [128, 144], so entubulated tissue is most compliant during the
early weeks post-injury. It is crucial to keep tissue stresses sufficiently low at this time to
prevent the fibrin clot from being significantly deformed before synthesis of nerve tissue begins.
If significant deformation occurs, regenerate synthesis may be disrupted.
As briefly mentioned, it should be noted that this model is only applicable to nerve conduit
materials which allow attachment of contractile capsule cells. Generally, it is observed that the
capsule maintains constant contact between the nerve trunk and the nerve conduit for collagen-
based scaffolds crosslinked by dehydrothermal (DHT) treatment, an observation that is
consistent with the no-slip modeling assumption. Other nerve conduit materials to which cells
cannot attach (e.g. silicone elastomer, collagen-based scaffolds crosslinked by EDAC) are better
described by the mechanical model developed by Brau, in which case arr - Umfb [137]. The
Brau model is a simplification of the thin capsule model when Es=O Pa and ts=0 Pim; effectively,
this is equivalent to removing the no-slip condition between the tissue and scaffold such that all
applied loads are balanced exclusively by the tissue.
Interestingly, in an in vivo study completed using a library of nerve conduits crosslinked by
DHT, drastic differences in regenerate quality are observed for scaffold stiffnesses lying within
the narrow range of 154-225 Pa [2]. For this range of conduit stiffnesses, there is no significant
difference in stresses and displacements within the tissue predicted by the thin capsule model.
This is partially due to an absence in consideration of conduit degradation, which decreases the
stiffness of the conduit over time dependent upon the degree of crosslinking [148]. Although
scaffold A is 154 Pa while scaffold D is 225 Pa at the time of implantation, scaffold A degrades
much faster and therefore experiences a more rapid decrease in stiffness during the first two
weeks post-transection. This leads to a rapid reduction in load attenuation by the scaffold, as
illustrated in Figures 2.6 and 2.7. When the scaffold degrades completely, the thin capsule
model again approaches the solution of the model developed by Brau (with tissue properties of
fibrin, not nerve tissue) and predicts relatively higher magnitude stress distributions and radial
deformations.
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The thin capsule model encapsulates all of the effects of the Brau model with additional
consideration of mechanical effects due to entubulation. However, this model does not take into
account the mechanical effect of a contractile capsule with finite thickness or the kinetics of
early stage peripheral nerve regeneration. Experimental data show that the capsule does indeed
have a finite thickness and is composed of multiple layers of contractile cells which increase in
number over time [5, 86, 112]. Because the capsule does have a finite thickness and associated
mechanical properties, it may have a similar attenuation effect as described for the conduit via
the thin capsule model. Further, the mechanical properties of all materials and the loading
applied by contractile cells may change over time. In the next section, one of these limitations
will be addressed by a second model which incorporates the mechanical effect of the contractile
capsule.
2.4 Multi-Layer (Finite Thickness) Capsule Model
The thin capsule model simplifies the capsule into a layer with infinitesimally small thickness,
but experimental data show that the capsule has a finite thickness of 5-100 pIm and is composed
of multiple layers of contractile cells, as shown in Figure 2.9 (left) [5, 86, 112]. Because the
capsule does have a finite thickness, it may also have a mechanical effect on peripheral nerve
regeneration which cannot be described by the Brau or thin capsule models. The objective of the
multi-layer capsule model is therefore to investigate the additional effects of capsule mechanical
properties on the stress distributions and radial deformations of the tissue.
The assumptions of the thin capsule model are also applicable in the multi-layer capsule model.
Figure 2.9 (right) shows the schematic for the model, in which the effects of capsule cell forces
on tissue deformation in the presence of a nerve conduit are described by modeling the capsule
as N additional concentric layers of contractile cells, each with thickness ti", located between the
tissue and scaffold layers. It is assumed that no-slip conditions are propagated through all
additional layers.
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uCapsule
Scaffold
Figure 2.9. Left: Histological image of a contractile capsule stained for a-SMA (brown/red) in a
silicone conduit with a gap length of 10 mm 60 weeks post-transection (scale bar is 10 Pm) [5].
Right: Schematic of the multi-layer capsule model.
For simplicity, it is assumed that the compressive load exerted by cells of the capsule is
consistently applied at the outer radius of each capsule layer (the load could also be consistently
exerted at the midline or inner radius of each capsule layer without affecting the conclusions of
this model). Due to the relatively small thickness and stiffness of the capsule layers in
comparison to those of the tissue and scaffold during the first two weeks post-transection (Table
2.1), this choice does not significantly affect model results.
2.4.1 Model Derivation
Equations 2.15-2.17 suggest that two integration constants exist for each cylindrical material
layer (A,B) added to a composite cylinder model, so there are a total of 4 (At, Bt, As, Bs) + 2*N
(Amn, Bmn for n=1 to N) constants required to fully describe the stress-strain relationships of the
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Tissue,
multi-layer capsule model. To determine these constants, boundary conditions are applied.
First, similar to the thin capsule model, a singularity will exist at r = 0 unless Bt = 0.
ut(0) = 0= Bt = 0 2.28
Second, the no-slip condition requires displacement continuity between the tissue and first
myofibroblast layers at Rt.
ut(Rt) = u"l(Rt) => At = A"n + Bm  2.29
Third, because the outer radius of the scaffold (RS) is a free surface
BSR
r(RS) = 0 -> ASCS + (1 - 2vs) (Rs)2 2.29
Fourth, because Rt is a load-free interface, the radial stress must be equal and opposite at the
interface to balance traction, providing
Am Cm + (1 - 2vm) BmRt2  -AtCt - (1 - 2vt) BtRt 2  2.30
(Rt 2 (Rt 2
where the mn superscript denotes the n myofibroblast layer for n=1 to N. Displacement
continuity at each myofibroblast layer interface gives N more equations
Am n Rn Bm Rt Am(n+l)Rn + Bm(n+Rt 2.31
Rt Rn Rt Rn
The last boundary condition arises from the equations that define the stresses applied by cells in
each capsule layer. If there were only one myofibroblast layer present, this equation would be
very similar to Equation 2.22 of the thin capsule model. However, as multiple layers are added,
they are coupled with other existing myofibroblast layers, making it difficult to explicitly
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determine the "effective" stress at any given radius. This can be explained by relating the total
hoop stress in one capsule layer (a" (Rn)) to the applied load, amfb:
2.32- P(Fn(n) CYO Rn =Cpf
where p represents all layers 1 to N except the layer of interest, n. For a three-myofibroblast
layer model, Equation 2.32 can be written as
oo (R1) - ay (R1) - ay (R1) = amfb
GO (R2)- 
-(R2) a (R 2 ) = amfb
aG (R3)- Y' (R 3 ) - aG (R 3 ) = Umfb
2.33
2.34
2.35
This is not possible to determine analytically because there are three equations and nine
unknowns. However, because myofibroblast layers are relatively thin, it can be approximated
that R1 ~ R2 ~ R3 ~ Rn. This approximation results in
G (Rn) = N * amfb 2.36
In summary, the system of equations that must
multi-layer capsule model is
1 -1 -1 0
0 0 0 CS
-Ct CS
0 Rn
0Rt
0 -C"'
(1 - 2v m)
(Rt)2
Rt
Rn
(2v m - 1)
(Rm )2
0
R
Rt
CS
be solved in order to determine the solution of the
0
(1 - 2vs)
(Rs )2
0
Rt
Rn
(2vs _ 1)
(Rs )2
At- 0
Am 0
Bm =0
As 0
Bs- .Namfb-
2.37
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After the constants are determined from the boundary conditions, they are substituted into
Equations 2.17 and 2.18 to provide expressions for the stress distributions and radial
deformations in each material. As in the thin capsule model, the stresses in the tissue are again
constant because the tissue is modeled as a solid cylinder.
2.4.2 Results
Figure 2.10 shows the relationship between number of myofibroblast layers and the resulting
radial/hoop stress magnitude in the tissue. It also demonstrates the attenuation of stress in the
tissue layer due to the scaffold and capsule compared to those predicted by the Brau model.
Figure 2.11 further shows that the radial/circumferential stress in the tissue decays as the
stiffness of the myofibroblast layers increases.
Effect of Capsule Cell Layers on Tissue Radial Stress
(ES = 225 Pa)
10-
Thin Capsule Model I
8 - - - Brau Model
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Figure 2.10. Radial/hoop stress in the tissue normalized against the applied contractile load by
capsule cells as a function of number of capsule cell layers.
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Tissue Stresses vs. Capsule Layer Stiffness (1 Layer Example)
0
0E 0
0
0.4- -0
0
0
0.2- 0,
00 1 2 3 410 10 10 10 10
Emfb/Et
Figure 2.11. Effect of myofibroblast layer stiffness on tissue radial/circumferential stress.
2.4.3 Discussion
The objective of the multi-layer capsule model was to investigate the mechanical effects of the
contractile cell capsule on the stress distributions and radial deformations of the tissue during
entubulated healing of transected peripheral nerves. Figure 2.10 shows that the multi-layer
capsule model predicts a linear increase in radial/hoop stress in the tissue as the number of
contractile cell layers increases. In the first two weeks post-transection as capsule cells migrate
into the gap, the capsule layer is mostly cellular with a relatively low stiffness, approximated
here around 100 Pa. As the capsule continues to grow, local contractile cells produce collagen
and other extra-cellular matrix (ECM) proteins in the capsule, while further actin polymerization
occurs simultaneously. These processes act to increase the stiffness of the capsule. Figure 2.11
illustrates that this effect further attenuates stresses in the tissue, which may explain why the
long-term wound healing response shows no further deformation of nerve tissue after 6 weeks
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[5]. Furthermore, the fibrin clot also gradually becomes stiffer during peripheral nerve wound
healing due to additional coagulation and local deformation by cells, allowing it to better resist
loads applied by contractile cells. As a result, this model is most useful in describing the
peripheral nerve wound healing response late (> 2 weeks post-injury) when cells of the capsule
begin to generate extra-cellular matrix (ECM) and impart significant stiffness to the capsule
layers.
In the long term, this model shows that the forces exerted by cells in the capsule layer are
attenuated not only by the nerve conduit, but also by the increasing stiffness of capsule cell
layers. It is interesting that the multi-layer capsule model is able to offer these results as a
possible explanation for the termination of tissue deformation beyond 6 weeks post-transection
[5]. This effect of diminished tissue deformation is further compounded later in wound healing
as the fibrin clot is replaced by nerve tissue approaching a stiffness of~500 kPa [144].
As the mechanical properties of the capsule layer approach those of the tissue and the thickness
of the capsule layer approaches zero, the multi-layer capsule model approaches the solution for
the thin capsule model. When capsule stiffness is less than or equal to tissue stiffness, the multi-
layer capsule model is unnecessary and the thin capsule model will accurately describe stress-
strain behavior. Otherwise, the multi-layer thickness capsule model should be used for increased
accuracy in describing the deformations and stress distributions in the tissue.
2.5 A Kinetic Model of Early Stage Wound Healing in Entubulated Peripheral
Nerves
In the models previously presented, wound healing is simplified into a static, elastic response
that is far from realistic. Although some information regarding the mechanical effect of a nerve
conduit used for entubulation during the wound healing process can be discerned from these
models, the important biological and chemical dynamics that drive wound healing are absent.
The thin and multi-layer capsule models show that tissue deformation due to compressive forces
from cells of the contractile capsule is dependent on the properties of the tissue, capsule, and
scaffold. However, these properties vary over time, particularly during the early stages of
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entubulated wound healing. Therefore, the kinetic processes that govern their behavior must be
integrated into current static models for increased relevance. The objective of the kinetic model
presented in this section is to describe the effect of nerve and capsule formation kinetics on the
early stages of wound healing and to identify which parameters most affect the wound healing
outcome. The kinetic model describes the wound healing process of early stage entubulated
peripheral nerves by a limited number of parameters using a quasi-static approach to estimate the
spatial-temporal response of peripheral nerve wound healing and more accurately describe the
effect of conduits on nerve regeneration.
2.5.1 Kinetics of Entubulated Peripheral Nerve Wound Healing
The early (first 1-2 weeks post-injury) stages of entubulated peripheral nerve wound healing can
be described by a series of elementary processes which interact and compete with one another to
determine the outcome of regeneration. During the first week post-transection, exudate fills the
gap between nerve stumps and fibrin polymerizes from fibrinogen and thrombin in the contained
plasma [112, 116]. At 3 days into the fibrin polymerization stage, endoneurial cells (Schwann
cells, fibroblasts, endothelial cells) that precede axon elongation begin to migrate through the
polymerizing fibrin toward the gap midpoint. Simultaneously along the periphery of the fibrin
clot, contractile cells that can apply forces and deform the fibrin clot begin to migrate and form
the concentric layers of the contractile capsule [116, 141]. It has been hypothesized previously
that the extent and quality of regeneration may depend on the relative speeds of these two
distinct cell fronts [16]. The mechanical model presented here studies the first 14 days post-
transection and attempts to describe the aforementioned "race" between nerve tissue formation
and contractile capsule formation. Figure 2.12 shows a schematic of the early stage steps of
peripheral nerve wound healing.
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Figure 2.12. Schematic depicting the elementary processes that occur 0-14 days after
transection and entubulation of peripheral nerves. The figure shows the left half of the gap, from
the proximal stump to the gap midpoint, where z is the coordinate along the nerve axis. First,
exudate secreted by the nerve stumps fills the conduit; fibrin begins polymerizing (days 0 to 7).
Around day 3, capsule cells (perineurial cells) and endoneurial cells (fibroblasts, Schwann cells,
endothelial cells) begin to migrate from the stumps toward the center of the gap around the
periphery and through the core of the fibrin clot, respectively. Cells of the capsule front, which
migrate at a faster rate, build a capsule around the fibrin clot. They then apply forces (magnitude
qualitatively illustrated by F(z) plots) to the compliant fibrin matrix.
Experimental data suggest that the capsule front migrates along the nerve axis toward the center
of the gap at a faster rate than the nerve front [116]. Consequently, when cells of the nerve front
reach a particular axial position (z) along the nerve axis, capsule cells have already arrived and
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are actively applying forces to the fibrin clot at that location. This evidence implies that nerve
front cells interact with fibrin that has already been compressed by contractile cells in the
surrounding capsule. Deformation of compliant fibrin reduces the framework available for
migration of the nerve front, which potentially disrupts the synthesis of new nerve tissue and the
downstream quality of the regenerate.
Like the thin capsule and multi-layer capsule models, this kinetic model relies on the hypothesis
that significant deformation of the fibrin clot prior to nerve synthesis results in a poor regenerate
(or possibly, a neuroma). Other assumptions mentioned in sections 2.3 and 2.4 are also
applicable. This kinetic model considers the processes of fibrin formation, nerve tissue
formation, and capsule formation, as shown in Figure 2.12. The three distinct processes are
described in further detail below.
Fibrin Formation: Fibrin formation is modeled by polymerization of exudate into a fibrin clot
with increasing Young's modulus, Et. Fibrin polymerization is described by three parameters.
Etmin is the minimum stiffness of fibrin that enables cell migration, Etmax is the maximum (steady
state) stiffness of a fully polymerized fibrin clot, and Tstiffness is the time constant of fibrin
polymerization. It is assumed that fibrin polymerization is homogenous along the nerve axis and
can be described by a first order exponential. The resulting Young's modulus of fibrin is:
Et(t) = (Emnax - Etin) 1 - exp (- t ) Et
m T~~stiffness) mi
Nerve Tissue Formation: Endoneurial cells (fibroblasts, Schwann cells, blood vessels) begin
migrating into the gap 3 days post-transection after fibrin polymerization has already begun
[113, 116]. The migration of endoneurial cells is modeled as a front that propagates from both
stumps toward the gap midpoint along the nerve axis with constant velocity, Vnf. The front of
endoneurial cells precedes the subsequent elongation of axons that attempt to restore signal
conduction between nerve stumps.
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Capsule Formation: The mechanisms of capsule growth are unknown, but the literature suggests
that both axial and radial kinetics play a role. Axial migration of perineurial cells into the gap is
observed approximately 3 days post-transection [141]. These cells are believed to develop from
the same precursor (fibroblasts) as the myofibroblasts which make up the contractile cell capsule
[149]. The migration of these cells is also modeled as a front that migrates from both nerve
stumps toward the gap midpoint with constant velocity, Vmf.
After arriving at a particular location, capsule cells begin to aggregate radially, causing the
thickness of the capsule to increase toward a maximum of N cell layers. Literature suggests that
the capsule is visible in multiple layers near the nerve stumps as soon as one week post-
transection [116, 141]. Further, variation in number of cell layers has been noted between the
stump and more distally near the cell front [141]. Based on this information, the kinetics of
radial capsule growth are modeled by a first-order exponential with time constant Tcapsule and
maximum thickness of N cell layers. Combining the axial and radial kinetics of capsule growth,
the force applied by cells of the contractile capsule is:
(t -z
Namz 1 - exp Vm b , z ; Vmfmt
a (z, t) = 10 ( TcapsuleZ 
> m t0 , z> Vmfft
where z is the distance from the proximal nerve stump.
In summary, the kinetics of wound healing during the first two weeks post-transection are
described by a model that contains seven parameters: nerve front velocity (Vhf), capsule front
velocity (Vmth), time constant of lateral capsule growth (Tcapsule), maximum number of capsule
cell layers (N), minimum and maximum stiffnesses of the fibrin clot (Etmin, Etmax), and time
constant of fibrin polymerization (Tstiffness). The range of each parameter is estimated based on
experimental data, as discussed in the following section.
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2.5.2 Modeling Parameter Estimation
Ranges for the modeling parameters discussed previously are obtained from relevant literature
and shown in Table 2.3. The majority of available experimental data are derived from
experiments in which rat sciatic nerves were entubulated with silicone nerve conduits. These
data are used to obtain the baseline set of parameters (Table 2.3), but it is known that the
experimental setup can affect parameter values [16, 83, 92, 112, 125]. Later, it will be further
discussed how nerve conduits of varied properties can potentially cause these values to lie in the
broader range noted by the "Variation" column of Table 2.3.
Table 2.3. Parameter values for the kinetics model of entubulated wound healing. Baseline
parameter values are derived from experiments using silicone conduits. Extended values
(denoted by the "Variation" column) are based on broad observations across various
experimental setups.
Parameter Description Baseline Value Variation
Etmax Maximum tissue stiffness 250 Pa [128] 58 Pa - 500 kPa [128, 144]
Etmin Minimum tissue stiffness 50 Pa [128] N/A
T
stiffness Fibrin polymerization rate 2 days [116] 0.5 - 5 days [116]
Tcapsule Capsule growth rate 2 days [83, 116] 0.5 - 5 days
N Number of layers 2 layers 1-10 layers [83]
Vmff Capsule front velocity 4 mm/wk [116] 3 - 10 mm/wk [83, 116]
Vaf Nerve front velocity 2.5 mm/wk [116] 0.5 - 3.5 mm/wk [116, 126]
The parameters of the three elementary processes (fibrin formation, nerve tissue formation, and
capsule formation) of peripheral nerve wound healing in its early stages are further discussed
below.
Fibrin Formation: There is very little data on the mechanical properties of in vivo fibrin clots.
Studies of in vitro clots have shown that typical fibrin clots of similar composition to those
observed in vivo typically have a Young's modulus ranging from ~50Pa-250Pa, depending on
the abundance of fibrinogen, thrombin, and Factor XIIIa [128, 133, 134]. Based on these data,
250 Pa was chosen to serve as the maximum stiffness (Etmax) of the fibrin clot in the peripheral
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nerve wound healing mechanical model, while the minimum stiffness (Etmin) that enables cell
migration was estimated at 50 Pa. The fibrin polymerization time constant (Tstiffness) is estimated
from published observations that fibrin polymerization is complete by 1 week [116]. Assuming
a linear time-invariant output response to a step input, steady state (4* Tstiffness) occurs by 1 week,
which yields Tstiffness 2 days.
Nerve Tissue Formation: The velocity of endoneurial cells (Vnf) is estimated at 2.5 mm/wk in
transected nerves entubulated by silicone nerve conduits based on observations of endoneurial
cells along the nerve axis at one, two, and three weeks post-transection [116].
Capsule Formation: Perineurial cells develop from the same precursor (fibroblasts) as the
myofibroblasts which make up the capsule [149], so axial capsule cell migration (Vmt,) is
estimated based on the in vivo observations of perineurial cells around the regenerate formed
within silicone conduits post-transection at 3, 7, 12, 18, and 21 days post-injury. These
observations suggest that perineurial cells typically migrate at a velocity of about 4 mm/week
[141]. The maximum number of layers observed (N) is based on data from in vivo observations
using silicone and collagen-based nerve conduits. In most experimental setups, N varies
between 1-10 layers, but 15 or more layers have occasionally been observed [5, 83, 116]. There
is limited background information regarding the radial growth kinetics of capsule cell layers,
particularly in the early stages of peripheral nerve regeneration. However, the capsule growth
time constant (Tcapsule) is estimated based on observations of a capsule around the fibrin clot as
soon as one week post-injury (steady state at 4 *Tcapsu1e= 7 days), which yields Tcapsule 2 days
[116].
2.5.3 Quasi-static Approximation
The kinetic model developed here describes the processes of fibrin formation, nerve tissue
formation, and capsule formation by assuming that cells of the nerve front respond to the time-
dependent mechanical properties of fibrin and forces applied by contractile cells of the
contractile capsule at a particular axial location when the nerve front arrives. Radial deformation
of the fibrin clot is therefore determined based on the environment to which nerve front cells are
exposed upon arrival.
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The parameter values that describe the environment are calculated by assuming that deformation
of one z-plane section (axial cross-section) of the fibrin clot does not significantly affect the
deformation of neighboring z-planes. At each time step, the current model parameters are
sampled and stored. In effect, a "snapshot" is taken at each time step by sampling the response
at the arriving location of the nerve front (Figure 2.13). We record the load magnitude applied
by cells of the capsule and the stiffness value of the fibrin clot at the unique axial location of the
nerve front at the corresponding time step. These data points are then used to generate force
applied (o(z,t)) vs. nerve front axial location and fibrin stiffness (Et(t)) vs. nerve front axial
location plots (at each time step) for preliminary analysis in MATLAB and subsequent analysis
in ADINA. In this study, MATLAB was used to separate the first two weeks post-transection
into 28 time steps (1 time step = 0.5 days) for analysis.
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Figure 2.13. Left: An example of the sampling process used to determine loading (ca(z,t)) and
stiffness (Et(t)) profiles for the mechanical model. The force applied by capsule cells is plotted
for time steps of 5 days (blue), 7 days (red), and 10 days (green). The axial location of the nerve
front is also plotted as a vertical line at 5 days (blue, dotted), 7 days (red, dotted), and 10 days
(green, dotted). The intersection of the axial location of the nerve front with the loading curve
for the corresponding time step (marked by black circles) is stored for each time point and used
to generate an applied force vs. z curve that considers the dynamics of the wound healing
process. A similar process is followed to determine the fibrin stiffness vs. z curve. The above
data are generated using the following parameters: Etmin=50 Pa, E'max=250 Pa, Tstiffness= 2 days,
Tcapsule= 2 days, Vnf=2.5 mm/wk, Vmfb= 4 mm/wk, N=2 cell layers. The load (vertical axis) is
normalized against amfb. Right: The resulting loading curve for the quasi-static approximation
example shown normalized against umfb.
2.5.4 Results
In all figures below, Et(t) and a(t) represent the fibrin stiffness and effective load profiles,
respectively. Figures 2.14 and 2.15 show the effect of capsule front and nerve front velocity,
respectively, on fibrin deformation. Figure 2.16 shows how the time constant of capsule growth
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affects fibrin deformation, while Figure 2.17 shows how the number of cell layers in the
contractile capsule affects fibrin deformation.
Figures 2.18 and 2.19 suggest that fibrin polymerization parameters can also affect fibrin
deformation. The effect of maximum fibrin stiffness is shown in the former while the effect of
the fibrin polymerization time constant is detailed in the latter. Finally, the effect of nerve front
velocity on fibrin deformation when the capsule front is extremely fast (10 mm/wk) is shown in
Figure 2.20, and the effect of disparity between capsule and nerve front velocities on fibrin
deformation plotted against nerve front velocity magnitude is plotted in Figure 2.21.
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Effect of Vmfb on Fibrin Deformation
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Figure 2.14. The effect of capsule front velocity (Vm>) on fibrin deformation (represented by the
ratio between effective load profile, a(t), and fibrin stiffness, Et(t)) as a function of the axial
distance from the proximal nerve stump (z) in millimeters. A faster capsule front results in
greater fibrin deformation.
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Figure 2.15. The effect of nerve front velocity (Vaf) on fibrin deformation (represented by the
ratio between effective load profile, a(t), and fibrin stiffness, Et(t)) as a function of the axial
distance from the proximal nerve stump (z) in millimeters. A faster nerve front results in less
fibrin deformation.
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Figure 2.16. The effect of capsule growth time constant (tcapsuie) on fibrin deformation
(represented by the ratio between effective load profile, a(t), and fibrin stiffness, Et(t)) as a
function of the axial distance from the proximal nerve stump (z) in millimeters. Faster capsule
growth results in greater fibrin deformation.
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Figure 2.17. The effect the number of capsule cell layers (N) on fibrin deformation (represented
by the ratio between effective load profile, a(t), and fibrin stiffness, Et(t)) as a function of the
axial distance from the proximal nerve stump (z) in millimeters. Deformation increases linearly
with number of layers.
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Figure 2.18. The effect of maximum fibrin stiffness (Emax) on fibrin deformation (represented
by the ratio between effective load profile, o(t), and fibrin stiffness, Et(t)) as a function of the
axial distance from the proximal nerve stump (z) in millimeters. Higher tissue stiffness results in
less deformation.
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Figure 2.19. The effect of fibrin polymerization time constant (tstifness) on fibrin deformation
(represented by the ratio between effective load profile, c(t), and fibrin stiffness, Et(t)) as a
function of the axial distance from the proximal nerve stump (z) in millimeters. Slower fibrin
polymerization results in greater fibrin deformation.
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Figure 2.20. The effect of nerve front velocity (Vaf) on fibrin deformation (represented by the
ratio between effective load profile, aT(t), and fibrin stiffness, Et(t)) as a function of the axial
distance (z) in millimeters from the proximal nerve stump when the capsule velocity (Vmt) is
very fast (10 mm/wk). A faster nerve front results in less fibrin deformation.
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Figure 2.21. The effect of the difference between capsule front velocity (Vm) and nerve front
velocity (Vaf) on the equivalent applied load (u(t)) normalized against tissue stiffiess (Et(t)) as a
function of the nerve front velocity (Vf). Fibrin deformation depends highly on both the
magnitude of these antagonistic parameters and the difference between them. Black asterisk
denotes baseline values as noted in Table 2.1.
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2.5.5 Numerical Solution by Finite Elements
The Brau, thin capsule, multi-layer capsule, and kinetic models all provide information regarding
the mechanics of peripheral nerve regeneration. They do not, however, describe how the
boundary conditions (specifically, fixation by suturing of nerve stumps inside the conduit) affect
stress distributions or deformations in the tissue. It is important to consider these boundary
conditions because fixation of nerve stumps may impart a mechanical effect near the nerve
stumps with the potential to propagate further into the gap. The significance of these effects
needs to be studied in order to validate the stress distributions and radial deformations predicted
by the thin, multi-layer, and kinetic models and more accurately model in vivo experimental
conditions.
Use of finite elements to obtain a numerical solution allows the boundary conditions of
entubulated peripheral nerve wound healing to be considered. First, an infinitesimal wedge (1
angle) with a tissue, capsule, and scaffold layer as defined in Table 2.1 was created in ADINA.
Then, symmetry (roller) boundary conditions were applied on the sides of the wedge and on one
end to mark the gap midpoint. The other end was fixed to account for entubulation.
Axisymmetry requires that the bottom of the wedge be fixed, and all remaining surfaces were left
free. These boundary conditions are shown in Figure 2.22.
r r
Front View Side View z 4
Figure 2.22. Schematic of boundary conditions for numerical solution.
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MATLAB was used to complete sampling for tissue stiffness and load profiles as a function of
axial location (z) for incorporation into finite element analysis (FEA) using ADINA as described
(Appendix B). The results presented in Figures 2.23 and 2.24 show the numerical solutions for
radial displacement and radial stress obtained for a relatively stiff two-layer capsule.
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Figure 2.23. Radial displacement due to baseline parameter values with Em=250 Pa.
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Figure 2.24. Radial stress distribution due to baseline parameter values with Em=250 Pa.
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Finally, Figure 2.25 shows a comparison between Brau's model, the three models presented in
this thesis, and a sample ex vivo experimental outcome (presented in Chapter 3 of this thesis).
Model results are for amff= 400 Pa per layer (or 1 cell applies 10 nN of force) and Ro = 750 pm
[16].
Model Comparisons to In Vivo Experimental Data
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Figure 2.25. Comparison of models to experimental data. The thin capsule model, multi-layer
model, and numerical solution derived from the kinetic model are better predictors of
experimental observations than the Brau model.
2.5.6 Discussion
Use of MATLAB allows consideration of the kinetics of the early stage wound healing response,
while subsequent implementation into ADINA allows visualization of the results of these
dynamics within three-dimensional space and with consideration of boundary conditions. The
overall effect is a more complete mechanical model considering both the mechanics and kinetics
of early stage entubulated peripheral nerve wound healing.
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The comparison between models and observed experimental data from this study (Chapter 3)
show that all three mechanical models described in this thesis can predict radial deformations of
nerve tissue on the correct order of magnitude (Figure 2.25). The kinetic model solved
numerically by finite element analysis most accurately predicts the experimental data, followed
by the multi-layer capsule model and finally the thin capsule model. As discussed earlier in this
chapter and shown in Figure 2.25, the Brau model underestimates radial deformation by several
orders of magnitude.
Particularly because this mechanical model deals with biological events, it is very possible that
use of nerve guides with varying properties could alter one or many of the modeling parameters
from those observed in the literature for silicone tubes. For example, nerve conduit fillings have
been shown to alter the structure of the fibrin clot that forms within the gap [92], which could
potentially affect its mechanical properties. Further, there is additional evidence that nerve
conduit fillings can affect both the migration speed of contractile cells along the periphery and
endoneurial cells into the gap [92, 112, 125]. The kinetic model of early stage regeneration
presented here shows that the relative velocities of these two cell groups play a critical role in
determining the degree of fibrin deformation (Figure 2.21). There is not enough data in the field
to predict these changes accurately. However, the effects of varying each modeling parameter
individually within a reasonable range based on observations in the literature while holding other
parameters constant (Table 2.3, Figures 2.14-2.21) offers the opportunity to examine the
sensitivity of the model to a range of parameter values.
The objective of the kinetic model was to describe how the kinetics of nerve and capsule
formation affect the early stages of wound healing. In general, the model predicts that a faster
capsule front velocity results in more radial deformation of fibrin (Figures 2.14 and 2.21), while
a faster nerve front velocity results in less radial deformation of fibrin (Figures 2.15, 2.20, and
2.21). These relationships exist because a significantly faster capsule front means that nerve
front cells encounter fibrin that has been already exposed to high steady state contractile forces
and significant deformation. As the nerve front velocity increases, the time in which capsule
layers can aggregate to form layers is reduced, which also reduces applied loads and fibrin
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deformation. Deformation of fibrin is most sensitive to capsule front velocity when it is less than
5 mm/week for the baseline parameter values chosen here, but Figure 2.21 suggests that fibrin
deformation depends highly on the relationship between capsule front velocity and nerve front
velocity in addition to the magnitude of each parameter. In the context of wound healing
processes, this model predicts that a faster nerve front will result in less fibrin deformation and a
higher quality regenerate, while a faster capsule front may quickly degrade the quality of
regeneration via excessive deformation of fibrin (Figures 2.14, 2.15, 2.20, and 2.21).
The extent of radial deformation is sensitive to the fibrin polymerization time constant when the
time constant is 3 days or fewer for the baseline parameter values studied (Figure 2.19). Figure
2.18 shows that maximum fibrin stiffness only significantly affects radial deformation of the
fibrin clot when the stiffness is very low (~50 Pa). An increase in number of capsule layers
results in an expected linear increase in effective load applied (Figure 2.17). The same is true of
the nerve front velocity (Figures 2.15 and 2.20). Effective loading curves are particularly
affected by the time constant of capsule growth. If the capsule thickness increases very rapidly
(steady state reached between 2 and 8 days), the loading profile is very sensitive, especially near
the proximal nerve stump (shown in Figure 2.16). In cases where many (> 10) layers form very
rapidly, these results suggest that significant deformation will occur closer to the proximal stump
than to the gap midpoint.
2.6 Model Limitations
In all three models presented in this thesis, linear elasticity is utilized to describe a viscoelastic
material. As such, it is recognized that there may be error in the analyses due to phenomena such
as creep, stress relaxation, sensitivity to rate of load application, or hysteresis. Further, many
parameter estimates used in this model are based on limited experimental information. A first
order exponential response was used in this work to set up a simple estimate for fibrin
polymerization and capsule thickness growth, but it is acknowledged that there may be multiple
ways to model both processes. Another assumption was that the magnitude of forces applied by
capsule cell layers is proportional to capsule thickness. This assumption has been used in
previous modeling work [137], but there is not sufficient evidence to claim it as a fact. This
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model also ignores any effects due to changes in cell signaling, expression of cytokines, and
nerve conduit degradation which could ultimately affect the magnitude of all parameters; there is
not enough experimental data at this point to accurately incorporate such effects.
The strength of this model, however, lies in its ability to effectively and simply incorporate the
pure mechanical effect of a nerve conduit and the kinetics of nerve and capsule formation into a
mechanical model of entubulated wound healing. Additionally, it is more accurate than existing
models in predicting experimentally observed radial deformation of tissue on the correct order of
magnitude (Figure 2.25). Furthermore, the model is extremely adaptable to alternative modeling
choices or parameter estimations (see codes in Appendix B) as more information becomes
available.
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Chapter 3: Imaging the Effects of Collagen Nerve Conduits on
Nerve Tissue and Capsule Formation
As discussed in Chapters 1 and 2, early stage entubulated wound healing of transected peripheral
nerves occurs in a series of elementary, interactive processes: fibrin formation, nerve tissue
formation, and capsule formation. Immediately after transection, exudate containing plasma is
secreted from the injured nerve stumps into the contained cavity. Fibrinogen in the plasma is
cleaved by thrombin to form a coagulated fibrin clot by the end of the first week post-transection
[12-14, 116]. Three days into fibrin polymerization, perineurial cells which later form the
capsule begin to migrate at the outer surface of the fibrin clot adjacent to the conduit, while
endoneurial cells that synthesize nerve tissue and precede axon elongation begin to migrate into
the fibrin core [113, 116, 141, 149]. The kinetic model of early stage entubulated peripheral
nerve wound healing presented in Chapter 2 suggests that the relative migration speeds of the
capsule and nerve fronts have a strong effect on the extent of fibrin deformation. This is
important because extensive deformation of fibrin may disrupt downstream processes of
regeneration by reducing the framework available to cells that later synthesize new nerve tissue.
During wound healing in severely injured peripheral nerves [16] and skin [6], it has been shown
that the physical and chemical properties of biomaterials can affect the quantity of contractile
cells. Observations of ex vivo transected rat sciatic nerves entubulated by several collagen
scaffolds suggest that the degradation rate of a nerve conduit affects the quality of new nerve
tissue [16]. Additional evidence that the mechanical and chemical properties of the nerve
conduit affect the early processes of wound healing comes from in vivo observations that
collagen conduits improve axon elongation, Schwann cell elongation, and the development of
new blood vessels in regenerates compared to silicone conduits [140]. The objective of the
experimental set presented in this chapter is to further study the effect of nerve conduit properties
on the formation of nerve tissue and the contractile cell capsule. This chapter provides ex vivo
experimental evidence that the mechanical and chemical properties of nerve conduits affect the
elementary wound healing processes of transected peripheral nerves.
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3.1 Materials and Methods
The objective of this study is to investigate the role of nerve conduit properties on nerve tissue
and capsule formation in transected peripheral nerves that have been entubulated by a nerve
conduit. To evaluate these effects, cross-sections of rat sciatic nerve entubulated with a 15 mm
gap between nerve stumps by scaffold devices D and E (Table 2.2) were selected for study at 1
and 2 weeks post-injury. Devices D and E were chosen because previous research indicates
drastic differences in regenerate quality at 9 weeks post-transection (with nerves entubulated by
device D displaying higher quality regeneration) [2]. The devices differ in many aspects,
including degradation rate, stiffness, and surface chemistry due to crosslinking by two different
methods: dehydrothermal crosslinking and chemical crosslinking (EDAC). It is possible that
some or all of these properties affect the wound healing outcome of transected peripheral nerves.
3.1.1 Choice of Ex Vivo Nerve Cross-sections
Nerve cross-sections were obtained from an in vivo rat sciatic nerve entubulation experiment,
conducted and described by Soller [2]. Briefly, the conduits used for entubulation are fabricated
from lyophilized and crosslinked type I bovine tendon collagen (5%). Conduit fabrication
protocols are previously described by Harley [148]. Soller implanted the homologous library of
scaffolds listed in Table 2.2 into female Lewis rats after transection of the left sciatic nerve. The
proximal and distal nerve stumps were inserted 3 mm into each end of the conduit, creating a 15
mm gap between stumps, and animals were sacrificed at 1, 2, and 9 weeks [2]. Harvested nerves
were immersed in Optimal Cutting Temperature (OCT) molds, then sectioned on a microtome
and placed on glass slides [2].
These sections (6 ptm thick) were used in this thesis to stain locations approximately every 2 mm
from the proximal stump (z = 0 mm) to the gap midpoint (z = 7.5 mm) as described below. The
nerve area, number of axons, number of Schwann cells, and axon density as a function of time (1
and 2 weeks) and location (z ~ 0, 2, 4, 6 mm) were used as metrics to determine the effect of
nerve conduit properties on the kinetics and quality of nerve tissue formation. Contractile
capsule thickness was measured to determine the effect of nerve conduit properties on capsule
formation.
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3.1.2 Immunofluorescent Staining of Nerve Sections
Cross-sections were harvested at 1 and 2 weeks post-transection. To quantify neural structures,
cross-sections were stained by immunofluorescence for Schwann cells (rabbit anti-S 100, Abcam,
ab76729, Cambridge, MA), axons (chicken anti-200 kD neurofilament, Abcam, ab72996,
Cambridge, MA), and cell nuclei (DAPI). To quantify capsule thickness, cross-sections were
stained by immunofluorescence for f-actin (rhodamine phalloidin, Invitrogen, R415), a-SMA
(Sigma, A2547), and cell nuclei (DAPI). Samples were then mounted and imaged (10x) using an
inverted fluorescent microscope (Olympus IX8 1, Van Vliet Lab, Department of Materials
Science and Engineering, MIT). See Appendix A for detailed protocols.
3.1.3 Quantification of Nerve Sections
The kinetics of early stage nerve tissue formation and capsule formation were evaluated by
monitoring the nerve area, number of axons, number of Schwann cells, axon density, and capsule
thickness as a function of two variables: time and location (see Figure 3.1).
Proximal Stump Fibrin Clot/Regenerate Distal Stump
15mm
z=2 mm z=6 mm
z=Q mm z=4 mm
Figure 3.1. Schematic of imaging locations for quantification of nerve sections. Cross sections
from the marked locations were stained at 1 and 2 weeks post-transection in this study.
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Following imaging, nerve sections were processed using ImageJ (available at
http://rsbweb.nih.gov/ij/download.html). ImageJ "Straight" line and "Measure" tools were used
to measure capsule thickness at three locations per nerve section for averaging. The cross-
sectional nerve area in each image (Anerve) was calculated using ImageJ "Freehand selections"
and "Measure" tools. A smaller known area, Aknown, was randomly selected and measured. In
Anown, the number of axons and Schwann cells (Ncount) were counted manually in three locations
(i=1 to 3) per sample, averaged, then scaled with total nerve area (Anerve) to estimate the total
number of axons or Schwann cells (Ntotal) per cross-section as:
Anerve i=1Ncounti 3.1
Ntotai 
- Akf 0 Wl 3Aknown 3
3.1.4 Statistical Methods
Data at each time point and location are presented as average ± the standard error of the means
(SEM). One-factor analysis of variance (ANOVA) tests were performed to determine the effect
of different nerve conduit crosslinking on the nerve area, number of axons, number of Schwann
cells, axon density, and capsule thickness at a particular time and location. Statistical
significance was accepted for p < 0.05.
3.2 Results
In order to compare nerve area, number of axons, number of Schwann cells, and density of axons
between nerve cross-sections obtained from rat sciatic nerves entubulated with devices D and E
(Table 2.2), samples were stained for Schwann cells, axons, and cell nuclei. Quantitative results
are presented in section 3.2.1.
In order to compare capsule thickness between nerve cross-sections obtained from rat sciatic
nerves entubulated with devices D and E (Table 2.2), nerve cross-sections were stained for a-
SMA, f-actin, and cell nuclei. Quantitative results are presented in section 3.2.2.
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3.2.1 Quantification of Neural Structures from Ex Vivo Nerve Samples
Figures 3.2-3.6 show representative images and quantification results based on ex vivo cross-
sections of nerve regenerates harvested at 1 and 2 weeks post-transection. Sections were
sampled in increments of 2 mm from the proximal stump toward the gap midpoint (all images
analyzed in this study can be found in Appendix C with exact locations). Specifically, Figures
3.2 and 3.3 show cross-sections harvested at t = 1 week post-transection at approximately z = 0
mm and 2 mm, respectively, for nerves treated with device D (left) and E (right). Figures 3.4,
3.5, and 3.6 show cross-sections from nerve samples harvested at t = 2 weeks post-transection at
approximately z = 0 mm, 2 mm, and 4 mm, respectively, for nerves treated with device D (left)
and E (right). No nerve tissue was observed in nerves treated with device E at z = 4 mm into the
gap at t = 2 weeks post-transection. In all figures, axons are shown in red, Schwann cells are
shown in green, and cell nuclei are shown in blue. The results of image quantification are
presented in Tables 3.1-3.5, which list the nerve area, axon and Schwann cell counts calculated
based on the procedure described above, and axon density. Tables 3.6 and 3.7 summarize the
average number of axons and Schwann cells (± SEM), respectively, at a given time and location;
Figures 3.7-3.10 present graphical summaries of each data set.
Figure 3.2. Fluorescent images of cross-sections obtained from transected rat sciatic nerves
entubulated with device D (left) or device E (right) and harvested 1 week post-transection.
Samples are obtained at the proximal stump (z ~ 0 mm). Red denotes axons, green denotes
Schwann cells, and blue denotes cell nuclei.
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Table 3.1. Number of axons and Schwann cells (mean ± SEM) per device
samples harvested 1 week post-transection.
at z ~ 0 mm for nerve
At this time point (t = 1 week) and location (z = 0 mm), there is no significant difference in nerve
area, number of axons, number of Schwann cells, or axon density, suggesting no effect of
conduit properties very close to the proximal stump at 1 week post-transection.
Figure 3.3. Fluorescent images of cross-sections obtained from transected rat sciatic nerves
entubulated with device D (left) or device E (right) and harvested 1 week post-transection.
Samples are obtained at approximately 2 mm from the proximal stump (z~ 2 mm). Red denotes
axons, green denotes Schwann cells, and blue denotes cell nuclei.
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Device Nerve area (sm 2) Number of Number of Axon Density
Axons Schwann cells (axons/sm2)
D 597000 ±32000 4190 ±610 3660± 1030 0.007 ±0.001
E 507000 ±55000 4160± 770 2460 1460 0.008 ±0.002
Table 3.2. Nerve area, number of axons, number of Schwann cells, and axon density (mean
SEM) per device at z ~ 2 mm for nerve samples harvested 1 week post-transection.
Device Nerve area Number of Number of Axon Density
(stm) Axons Schwann cells (axons/Im2)
D 690000 3710 600 3440± 180 0.005 ±0.002
99000
E 752000± 8000 1570 11 1370± 40 0.002 ±0.00004
At this time point (t = 1 week) and location (z = 2 mm), there is no significant difference in
number of axons or nerve area, but there are significantly more Schwann cells present in device
D and axon density is higher. This suggests a potential effect of conduit properties on Schwann
cell migration as early as 1 week post-injury.
Figure 3.4. Fluorescent images of cross-sections obtained from transected rat sciatic nerves
entubulated with device D (left) or device E (right) and harvested 2 weeks post-transection.
Samples are obtained at the proximal stump (z ~ 0 mm). Red denotes axons, green denotes
Schwann cells, and blue denotes cell nuclei.
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Table 3.3. Nerve area, number of axons, number of Schwann cells, and axon density (mean
SEM) per device at z ~ 0 mm for nerve samples harvested 2 weeks post-transection.
Device Nerve area (pm 2) Number of Number of Axon Density
Axons Schwann cells (axons/Im 2)
D 555000± 12000 3610± 300 3880 ±80 0.007 ±0.001
E 639000± 50000 4570± 170 1780± 1160 0.007 ± 0.001
At this time point (t = 2 weeks) and location (z = 0 mm), there is no significant difference in
nerve area, number of axons, or number of Schwann cells. Nerve area is significantly larger in
device E, suggesting a possible effect of conduit properties very close to the proximal stump at 2
weeks post-transection.
Figure 3.5. Fluorescent images of cross-sections obtained from transected rat sciatic nerves
entubulated with device D (left) or device E (right) and harvested 2 weeks post-transection.
Samples are obtained at approximately 2 mm from the proximal stump (z ~ 2 mm). Red denotes
axons, green denotes Schwann cells, and blue denotes cell nuclei.
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Table 3.4. Nerve area, number of axons, number of Schwann cells, and axon density (mean
SEM) per device at z ~ 2 mm for nerve samples harvested 2 weeks post-transection.
Nerve area (tm 2) Number of
Axons
Number of Schwann
cells
Axon Density
(axons/pm 2)
D 840000± 75000 3690 ±370 2660± 810 0.004 ±0.001
E 352000 ±208000 520 ±190 110 ±10 0.001 ±0.001
At this time point (t = 2 weeks) and location (z = 2 mm), there are significantly more axons and
Schwann cells in a nerve entubulated by device D, but no significant difference in nerve area or
axon density. This suggests a potential effect of conduit properties on nerve tissue formation at 2
weeks post-transection.
Figure 3.6. Fluorescent image of a cross-section obtained from a transected rat sciatic nerve
entubulated with device D and harvested 2 weeks post-transection approximately 4 mm from the
proximal stump (z ~ 4 mm). No nerve was visible at the same axial location for a nerve
entubulated with device E. Red denotes axons, green denotes Schwann cells, and blue denotes
cell nuclei.
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Device
Table 3.5. Nerve area, number of axons, number of Schwann cells, and axon density (mean
SEM) per device at z ~ 4 mm for nerve samples harvested 2 weeks post-transection.
Device Nerve area Number of Number of Axon Density
(pm2) Axons Schwann cells (axons/pm2)
D 759000 ±14000 680 80 130 ±30 0.0009 ±0.0001
E nerve not nerve not nerve not reached nerve not reached
reached reached
At this time point (t = 2 weeks) and location (z = 4 mm), the presence of axons and Schwann
cells only in device D suggests a potential effect of conduit properties on nerve tissue formation
at 2 weeks post-transection.
A summary of the data presented in Tables 3.1-3.5 are listed in Tables 3.6 (axons) and 3.7
(Schwann cells) and graphically represented in Figures 3.7-3.10.
Table 3.6. A summary of axon counts for device D and
proximal stump (1 and 2 weeks post-transection).
Table 3.7. A summary of Schwann cell counts for device D
from the proximal stump (1 and 2 weeks post-transection).
device E at 2 mm intervals from the
and device E at 2 mm intervals
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Device D Device E
1 week, z = 0 mm 4190 610 4160 770
1 week, z = 2 mm 3710 600 1570 11
2 weeks, z = 0 mm 3610 300 4570 170
2 weeks, z = 2 mm 3690 370 520 190
2 weeks, z = 4 mm 680 ± 80 nerve not reached
Device D Device E
1 week, z = 0 mm 3660 1030 2460 1460
1 week, z = 2 mm 3440 180 1370 ± 40
2 weeks, z = 0 mm 3880 80 1780 1160
2 weeks, z = 2 mm 2660 810 110 10
2 weeks, z = 4 mm 130 30 nerve not reached
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Figure 3.7. Summary of nerve area measurements for transected nerves treated with device D or
device E collagen scaffolds harvested 1 and 2 weeks post-transection. Data obtained from cross
sections sampled at 2 mm intervals from the proximal stump, N=2 samples per position per time.
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Figure 3.8. Summary of axon counts for transected nerves treated with device D or device E
collagen scaffolds harvested 1 and 2 weeks post-transection. Data obtained from cross sections
sampled at 2 mm intervals from the proximal stump, N=2 samples per position per time.
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Figure 3.9. Summary of Schwann cell counts for transected nerves treated with device D or
device E collagen scaffolds harvested 1 and 2 weeks post-transection. Data obtained from cross
sections sampled at 2 mm intervals from the proximal stump, N=2 samples per position per time.
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Figure 3.10. Summary of axon density measurements for transected nerves treated with device
D or device E collagen scaffolds harvested 1 and 2 weeks post-transection. Data obtained from
cross sections sampled at 2 mm intervals from the proximal stump, N=2 samples per position per
time. Normal axon density is based on axon counts from a contralateral sample.
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3.2.2 Quantification of Capsule Thickness From Ex Vivo Nerve Samples
Figures 3.11-3.16 show representative results of staining ex vivo cross-sections of nerve
regenerates harvested at 1 and 2 weeks post-transection in increments of 2 mm from the
proximal stump toward the gap midpoint (all images analyzed in this study can be found in
Appendix D with exact locations). Specifically, Figures 3.11 and 3.12 show cross-sections
harvested at t = 1 week post-transection at approximately z = 0 mm and 2 mm, respectively, for
nerves treated with device D (left) and E (right). Figures 3.13, 3.14, and 3.15 show cross-
sections from nerve samples harvested at t = 2 weeks post-transection at approximately z = 0
mm, 2 mm, and 4 mm, respectively, for nerves treated with device D (left) and E (right). No
capsule was observed around nerves treated with device E at z = 4 mm into the gap at t = 2
weeks post-transection. In all figures, f-actin is shown in red, a-SMA is shown in green, and cell
nuclei are shown in blue. Table 3.8 summarizes capsule thickness measurements (± SEM) at
given times and locations. Figure 3.16 presents the summary graphically.
Device D Device E
1 week 1 week
Figure 3.11. Fluorescent images of cross-sections obtained from transected rat sciatic nerves
entubulated with device D (left) or device E (right) and harvested 1 week post-transection.
Samples are obtained at the proximal stump (z 0 mm). Red denotes f-actin, green denotes a-
SMA, and blue denotes cell nuclei.
At this time point (t = 1 week) and location (z = 0 mm), the capsule thickness surrounding the
nerve entubulated by device E is significantly greater than observed in device D, suggesting a
potential effect of conduit properties very close to the proximal stump at 1 week post-transection.
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Figure 3.12. Fluorescent images of cross-sections obtained from transected rat sciatic nerves
entubulated with device D (left) or device E (right) and harvested 1 week post-transection at
approximately 2 mm from the proximal stump (z ~ 2 mm). Red denotes f-actin, green denotes a-
SMA, and blue denotes cell nuclei.
At this time point (t = 1 week) and location (z = 2 mm), there is no significant difference in
capsule thickness, suggesting no effect of conduit properties on capsule formation at 1 week
post-transection further into the gap.
Figure 3.13. Fluorescent images of cross-sections obtained from transected rat sciatic nerves
entubulated with device D (left) or device E (right) and harvested 2 weeks post-transection.
Samples are obtained at the proximal stump (z ~ 0 mm). Red denotes f-actin, green denotes a-
SMA, and blue denotes cell nuclei.
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At this time point (t = 2 weeks) and location (z = 0 mm), the capsule thickness surrounding the
nerve entubulated by device E is significantly greater than observed in device D, suggesting a
potential effect of conduit properties on capsule formation at 2 weeks post-transection near the
proximal stump.
Device D Device E
2 weeks 2 weeks
z~2 mm zZ~2 mm
Figure 3.14. Fluorescent images of cross-sections obtained from transected rat sciatic nerves
entubulated with device D (left) or device E (right) and harvested 2 weeks post-transection at
approximately 2 mm from the proximal stump (z 2 mm). Red denotes f-actin, green denotes a-
SMA, and blue denotes cell nuclei.
At this time point (t = 2 weeks) and location (z = 2 mm), there is no significant difference in
capsule thickness, suggesting no effect of conduit properties on capsule formation further into
the gap at 2 weeks post-transection.
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Device D
2 weeks
z = 4 mm
Figure 3.15. Fluorescent image of a cross-section obtained from a transected rat sciatic nerve
entubulated with device D and harvested 2 weeks post-transection at approximately 4 mm from
the proximal stump (z ~ 4 mm). No capsule was visible at the same axial location for a nerve
entubulated with device E. Red denotes f-actin, green denotes a-SMA, and blue denotes cell
nuclei.
At this time point (t = 2 weeks) and location (z = 4 mm), the presence of a capsule only in device
D suggests a potential effect of conduit properties on capsule formation at 2 weeks post-
transection.
Table 3.8. A summary of capsule thickness measurements (pim) for device D and device E at 2
mm intervals from the proximal stump (1 and 2 weeks post-transection).
Device D Device E
1 week, z = 0 mm 32.9 8.4 102.9 1.0
1 week, z = 2 mm 25.4 ±2.6 62.8 9.2
2 weeks, z = 0 mm 30.4 ±1.9 79.0 5.6
2 weeks, z = 2 mm 40.1 ± 7.6 89.9 16.3
2 weeks, z = 4 mm 35.5 ±3.4 no capsule
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Figure 3.16. Summary of capsule thickness measurements for transected nerves treated with
device D or device E collagen scaffolds harvested 1 and 2 weeks post-transection. Data obtained
from cross sections sampled at 2 mm intervals from the proximal stump, N=2 samples per
position per time.
3.3 Discussion
Consistent with previous observations by Harley [150] at 9 weeks post-transection, nerves
treated with both homologous devices D and E result in regenerates with a defined fascicle of
axons grouped together by connective tissue even as soon as 2 weeks post-injury. There was
however a significant difference in nerve structure for nerves treated with both devices D and E
near the leading edge of what appear to be the axon and Schwann cell elongation fronts. Axons
generally elongate axially through the gap, perpendicular to the imaging plane (as shown in
Figures 3.2-3.4 and 3.5, left). The axons in nerves treated with devices D and E at locations in
the gap which have not yet formed defined fascicles appear to instead lie parallel to the imaging
plane (Figures 3.5, right and 3.6), as if inadequate guidance causes the axons to get "lost" in the
cavity of the tube. Further, the number of axons reported here for 1-2 weeks post-transection is
higher for nerves treated with both devices D and E than those reported previously at 9 weeks
near the gap midpoint [2]. These two observations together may support the hypothesis that
97
"lost" axons degenerate between 2 and 9 weeks post-transection after failing to connect the
proximal and distal stumps [151].
In all samples sacrificed from animals at one week post-transection, axons and Schwann cells
were visible at 2 mm from the proximal stump (Figs. 3.2-3.3, Tables 3.1-3.2). This is consistent
with the estimates of Schwann cell migration (2.5 mm/week starting 3 days post-transection)
observed by Williams, et al. in silicone conduits [113, 116]. Close to the point of nerve
transection (z ~ 0 mm), there was no significant difference in nerve area (p > 0.29), number of
axons (p > 0.97), number of Schwann cells (p > 0.57), or axon density (p > 0.33) revealed by one
factor ANOVA testing. Samples from one week post-transection harvested from 2 mm into the
gap, however, were revealed to have significantly more Schwann cells (p < 0.008) in nerves
treated with device D but no significant difference in axon density (p > 0.30), number of axons
(p > 0.10), or nerve area (p > 0.59).
In samples sacrificed from animals at 2 weeks post-transection, axons and Schwann cells were
visible at 2 mm from the proximal stump in regenerates entubulated by device E and at 4 mm
from the proximal stump in regenerates entubulated by device D (Figs. 3.4-3.6, Tables 3.3-3.5).
In the proximal stump (z ~ 0 mm), there was no significant difference in nerve area (p > 0.35),
number of axons (p > 0.08), number of Schwann cells (p > 0.21), or axon density (p > 0.29)
revealed by one factor ANOVA testing. Samples harvested from 2 mm into the gap were
revealed to have significantly more axons (p < 0.033) and Schwann cells (p < 0.002) in
regenerates entubulated by device D, but no significant differences were found between nerve
area (p > 0.15) and axon density (p > 0.59). Samples harvested from 4 mm into the gap only
show nerve tissue in regenerates entubulated by device D.
Consistent with previous results published in this laboratory regarding the quality of nerve tissue
at later time points [1, 2], these results collectively suggest that device D results in faster axon
elongation and Schwann cell migration than device E during early wound healing. These
observations support the hypothesis that formation of nerve tissue is indeed affected by the
properties of the biomaterial chosen for entubulation and that active biomaterials (e.g. device D)
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accelerate the formation of new nerve tissue during early time points compared to inactive
biomaterials (e.g. device E).
This chapter also presented nerve cross-sections obtained from rat sciatic nerves entubulated
with devices D and E and stained for f-actin, a-SMA, and cell nuclei. Consistent with previous
observations in peripheral nerves at 9 weeks post-transection [16], the results show that the
mechanical and chemical properties of devices D and E (imparted by different crosslinking
methods) may also have an effect on capsule thickness as early as 1 and 2 weeks post-
transection. This effect was particularly evident near the proximal stumps, where the thickness
of the capsule surrounding nerves in device E was significantly thicker than the capsule
surrounding nerves in device D at 1 week (p < 0.02) and 2 weeks (p < 0.02) post-transection.
Approximately 2 mm from the proximal stump, no significant difference in capsule thickness
was observed at 1 week (p > 0.06) or 2 weeks (p > 0.10) post-transection. Interestingly, at 2
weeks post-transection and 4 mm from the proximal stump, a capsule was only visible around
the nerve entubulated by device D. This observation suggests that there may be an effect of
nerve conduit properties on the migration of capsule cells into the gap during the first 2 weeks of
entubulated wound healing.
Because the two kinds of collagen scaffolds (D and E) studied in this thesis can vary in several
properties (including degradation rate, stiffness, and surface chemistry due to crosslinking by
two different methods), it is difficult to isolate the specific property that results in the observed
differences in nerve tissue and capsule formation. Future work investigating the effect of nerve
conduit properties on the quality and kinetics of regeneration could improve this analysis through
additional in vivo experiments using another library of homologous conduits with a single
varying parameter. Further, more detailed tracking of Schwann cells, axons, myofibroblasts, and
even endoneurial cells into the gap would reveal extended insight on the mechanisms that control
the early processes of nerve tissue and capsule formation. These elementary processes could
potentially be studied in vivo by a wide-field imaging technique that has been used previously to
image fluorescently-labeled axons in the central nervous system [152].
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Chapter 4: An In Vitro Model for Studying the Effects of
Biomaterials on Capsule Formation During Wound
Healing
During wound healing in severely injured peripheral nerves, it has been shown that the physical
and chemical properties of nerve conduits can affect both the quality of new nerve tissue and the
thickness of the contractile capsule surrounding the nerve [16]. These observations are similar to
those made previously in skin wound healing [6]. However, little is known regarding the
specific mechanical, chemical, and biological processes that regulate wound healing outcomes
and how they are affected by individual biomaterial properties. This chapter describes the
development of a new in vitro model that attempts to emulate the environment of cells that
become contractile during the early stages of peripheral nerve wound healing. Specifically, an
interface between fibrin and the biomaterial of interest is created to study the effect of
biomaterial properties on the formation of the contractile cell capsule (see Figure 4.1).
Immediately after injury, the gap between entubulated nerve stumps fills with exudate released
from the injured stumps and forms a fibrin clot within the first week post-transection [112, 116].
Approximately 3 days post-transection, cells that later form the contractile capsule migrate into
the gap from the stumps at the interface between the fibrin clot and the inner surface of the
conduit [141]. During the early (< 2 weeks post-injury) time points when contractile cells begin
to apply forces to entubulated tissue, the tissue is composed primarily of compliant fibrin with a
Young's modulus of 50-250 Pa [128]. At 9 weeks post-transection, there is evidence of an
inverse correlation between the thickness of the contractile cell capsule and the quality of the
resulting regenerate [16], suggesting that contractile forces applied by myofibroblasts may
directly affect peripheral nerve regeneration. Therefore, it is extremely relevant to study how
cells that become contractile behave in contact with fibrin and biomaterials.
The behavior of fibroblasts in fibrin gels and three-dimensional fibrin clots fabricated with
commercial fibrin sealant products has been previously studied. Cell spreading, migration, and
proliferation are highly dependent on the concentration of fibrinogen, thrombin, and Factor XIII
(fibrin-stabilizing factor, or FSF) that compose the fibrin [133, 135, 153]. These effects are so
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strong that drastic differences in fibroblast behavior have been observed even between different
batches of commercially-produced products [133, 134]. An absence of crosslinked fibronectin in
fibrin clots has been shown to prevent migration of fibroblasts and to slow cell spreading, but
does not appear to be a requirement for cell attachment and force application [154-156].
The effect of biomaterial properties on the contractility of fibroblasts in the presence of fibrin
and a biomaterial is studied in this chapter through an in vitro experiment. In vivo, cells that
form the contractile cell capsule migrate from transected nerve stumps along the periphery of the
fibrin clot, in contact with both fibrin and the entubulation device (if applicable). To create an in
vitro environment analogous to these in vivo conditions, it was required to develop an assay
which keeps fibroblasts in contact with both fibrin and the biomaterial of interest for the duration
of culture. For potential future imaging with confocal microscopy while keeping the fibrin-cell-
biomaterial "sandwich" intact, thin (on the order of 1-10 pm) fibrin surfaces were desirable.
Integration of these requirements into a repeatable assay which evaluates the effect of a
biomaterial on cell contractility in the presence of fibrin is discussed in the following section.
4.1 Materials and Methods
As in the nerve tissue and capsule formation study presented in Chapter 3, devices D and E
(Table 2.2) are the biomaterials of interest in this study based on previous research indicating
drastic differences in regenerate quality at 9 weeks post-transection [2]. This choice of
biomaterials also provides increased relevance to the nerve tissue formation study. Devices D
and E are crosslinked by dehydrothermal (DHT) and chemical (EDAC) methods, respectively,
resulting in scaffolds with very different degradation rates, stiffnesses, and chemical properties.
In vivo, cells that form the contractile cell capsule remain in contact with the fibrin clot formed
from exudate and the biomaterial used for entubulation for the duration of wound healing. To
evaluate the effects of conduit properties in vitro on the contractility of fibroblasts in the
presence of fibrin, a-SMA expression of fibroblasts cultured between fibrin and scaffold devices
D and E was monitored. This setup required i.) development of a standard process for
fabrication of fibrin surfaces to serve as analogs to in vivo fibrin clots, and ii.) development of an
assay which can be used to evaluate and compare the effects of various biomaterials on the
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differentiation of fibroblasts into the myofibroblast phenotype (marked by a-SMA expression)
while in the presence of fibrin.
4.1.1 Description and Fabrication of Thin Fibrin Surfaces
This section describes the process developed to fabricate thin fibrin surfaces that can act as
analogs to in vivo fibrin clots formed between entubulated nerve stumps after transection. In
vivo, fibrin clots form during the first week post-transection [112, 116]. By one week post-
injury, cells that form the contractile capsule can be observed between the fibrin clot and the
biomaterial used for entubulation. Because it is desired to develop an in vitro model that can be
used to study the effects of biomaterials on capsule formation, it is necessary to develop an
experimental setup that can place human dermal fibroblasts (HDF) in contact with fibrin and a
biomaterial.
To emulate the in vivo environment in vitro, thin fibrin surfaces were fabricated on glass
coverslips. A small area of fibrin was isolated with polydimethylsiloxane (PDMS) to create a
contained area for cell culture and subsequent placement of a biomaterial on top of cultured
cells. The schematic shown in Figure 4.1 shows the derivation of this in vitro setup from in vivo
conditions. Detailed protocols are described in the following section and in Appendix A.
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Proximal Stump Fibrin Clot/Regenerate Nerve Conduit Distal Stump
/ Contractile Cell Capsule
BiomaterialBiomaterial
--PDMS
Fibrin
Coverslip
Human Dermal Fibroblasts (HDF)
Figure 4.1. Schematic of the interface between nerve conduit (white) and the fibrin clot (green)
that forms early in the process of peripheral nerve wound healing. Cells that form the contractile
cell capsule (red) migrate into the gap at this interface. This complex environment is simplified
into a layered structure (cross-section shown at bottom right) for the in vitro model developed in
this thesis.
Fibrin clots that form in vivo when thrombin cleaves fibrinogen contain approximately 5-10%
fibronectin [12-14]. To mimic these fibrin clots, a fibrin solution was prepared by combining
fibrinogen (Sigma, F8630), thrombin (Sigma, T7513), and optional fibronectin (Sigma, F-4759)
in PBS supplemented with 5mM CaCl2 for proper thrombin activation. The solution was stored
in a cell incubator at 37'C and 5% CO 2 for 30 minutes to allow fibrin to polymerize. In order to
homogenously attach polymerized fibrin to a flat surface, glass coverslips (22x22 mm, VWR)
were treated in a plasma cleaner to decrease their hydrophobicity. Then, 3 pl of fibrin (+/-
fibronectin) was spread evenly over the surface using a pipette tip. Making the surfaces more
hydrophilic via plasma treatment increases the surface area that can be covered by the same
volume of fibrin, resulting in fibrin coatings approximately 2-3 ptm thick. Treated coverslips
coated with fibrin were immediately flash frozen by immersion in liquid nitrogen and
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lyophilized at a constant cooling rate (i. 10 minutes, atmospheric pressure, -40'C, ii. 15 minutes,
100 mTorr, -40'C, iii. 600 minutes, 100 mTorr, 4'C, iv. 120 minutes, 100 mTorr, 20'C) to create
a homogeneous microstructure (Figure 4.2). After lyophilization, dry fibrin coatings on glass
coverslips were crosslinked by dehydrothermal treatment (DHT) for 48 hours at 120'C.
Detailed protocols for this procedure can be found in Appendix A.
Figure 4.2. Fluorescent image that highlights the microstructure and nucleation pattern of a
lyophilized fibrin surface. Fibrin is supplemented with 10% fibronectin (Sigma, F-4759) and
fluorescein-conjugated Dextran (Sigma, FD4, 1:1000).
Polydimethylsiloxane (PDMS, SYLGARD@ 184 silicone elastomer kit, Dow Coming) was used
to create 8 mm diameter wells with an 8 mm diameter biopsy punch (Miltex, 52443) for
containment of human dermal fibroblast (HDF) cell cultures. PDMS wells were then pressed
securely against lyophilized fibrin surfaces prior to seeding with HDF. Air bubbles were
carefully removed to prevent leaking. Density of cell seeding had a critical impact on cell
behavior which will be discussed later. After seeding, HDF were incubated at 37'C and 5% CO 2
for 1-2 hours to allow for extensive cell attachment to fibrin. Finally, optional disks of collagen
devices D and E, fabricated and crosslinked as described in Appendix A and Table 2.2, were cut
into 8 mm disks (3 mm thick) using an 8 mm diameter biopsy punch (Miltex, 52443). Cell
medium (DMEM + 10% FBS + 1% penicillin and streptomycin, Invitrogen 11965092,
16000036, 15140148) was changed daily. If desired, cells were stimulated with transforming
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growth factor-p 1 (TGF-p 1, 5 ng/ml) for the duration of culture to upregulate expression of a-
SMA. Cell cultures on glass surfaces were created by simply pressing PDMS wells directly onto
glass coverslips followed by direct seeding of HDF as described in Appendix A.
4.1.2 Immunofluorescent Staining and Imaging
Cells cultured on fibrin and glass surfaces inside 8 mm diameter PDMS wells were fixed with
4% paraformaldehyde on 1, 3, and 5 days post-seeding, then stained for f-actin (rhodamine
phalloidin, Invitrogen, R415), cell nuclei (DAPI), and optionally, a-SMA (Sigma, A2547).
An inverted fluorescent microscope (Olympus IX8 1, Van Vliet Lab, Department of Materials
Science and Engineering, MIT) was used to image stained cells; images were processed using
ImageJ. Samples stained for only f-actin and cell nuclei were used to determine the effect of the
substrate (fibrin versus glass) on the aspect ratio of HDF. Aspect ratio was calculated by using
ImageJ "Straight" line and "Measure" tools to measure the ratio between long and short axes of
cells on fibrin and glass surfaces. At least twenty cells were measured on each of three glass or
fibrin samples fixed 1, 3 and 5 days post-seeding.
Samples stained additionally for a-SMA (Table 4.1) were studied qualitatively to determine
whether the presence of a biomaterial has a significant effect on a-SMA expression, an indicator
of differentiation into the myofibroblast phenotype observed in the contractile cell capsule that
forms during wound healing of peripheral nerves. Control samples of HDF in contact with fibrin
only (no biomaterial) on day 1 were fixed as a negative a-SMA control. Other samples were
sacrificed on days 3 and 5 to evaluate cell contractility by staining for a-SMA, f-actin, and cell
nuclei. Day 5 samples on glass stimulated with TGF-pl (no biomaterial) were used as a positive
a-SMA control. At least three samples were fixed and stained for each experimental variation
listed in Table 4.1. Detailed protocols for all procedures are described in Appendix A.
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Table 4.1. Samples for capsule formation study.
Fibrin TGF-pl Biomaterial
+ - Device D
+ - Device E
+ + Device D
+ + Device E
4.1.3 Statistical Methods
Data are presented as the average ± standard error of the means (SEM). One-factor analysis of
variance (ANOVA) tests were performed to determine the effect of substrate (glass versus fibrin)
on the aspect ratio of cultured cells. Statistical significance for quantitative comparisons was
accepted for p < 0.05.
4.2 Results
Qualitative and quantitative observations describing the behavior of human dermal fibroblasts
(HDF) on fibrin surfaces are presented first below. Then, observations regarding differentiation
of HDF into the myofibroblast phenotype on fibrin are presented. Finally, a-SMA expression
observed for cells cultured in contact with two different biomaterials is discussed.
4.2.1 Fibroblast Survival on Fibrin Surfaces
Spontaneous cell death was often observed on the third day of cell culture on fibrin surfaces. To
determine whether seeding density was responsible, cells were seeded at densities between 5-200
106
cells/mm2 on fibrin surfaces with and without fibronectin (10%). Seeding cells on fibrin both
with and without fibronectin resulted in spontaneous cell death for approximately 75% of
samples 3 days after initial seeding when fewer than 1000 cells (20 cells/mm 2 ) were seeded. In
general, seeding more cells resulted in more consistent viability of samples. A subsequent study
of cells cultured on fibrin surfaces with higher percentages of fibronectin (5%, 10%, and 20%
fibronectin samples were tested) revealed that cells are also more robust on fibrin surfaces with
higher percentages of fibronectin.
In order to quantify changes in cell morphology on glass versus fibrin substrates, cells were
seeded by covering glass/fibrin surfaces contained by PDMS wells in cell medium and
equilibrating the system at 37 0C and 5% CO 2. Cells were then seeded at 200 cells/mm 2 . Figure
4.3 shows representative pictures of HDF on glass and fibrin 1, 3, and 5 days post-seeding.
Table 4.2 shows the average aspect ratio of HDF on fibrin and glass surfaces observed after
fixation at the same time points.
Figure 4.3. Human dermal fibroblasts (HDF) cultured on fibrin (top row) and glass (bottom
row) surfaces. Cells were fixed at 1 (left column), 3 (middle column), and 5 (right column) days
post-seeding and stained with rhodamine phalloidin and DAPI. Scale bar = 10 pm.
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Table 4.2. Aspect ratios observed for HDF seeded on glass and fibrin surfaces (average ± SEM).
Day Glass Fibrin
1 4.74 ±0.14 3.66 ±.0.15
3 5.60 ±0.19 5.65 ± 0.23
5 5.03 ± 0.23 6.58 ± 0.28
One day after seeding, cells on glass adopt a spindle-like morphology, while cells on fibrin
appear shorter and wider, reflected by a significantly smaller (p < 0.001) aspect ratio as listed in
Table 4.2. By day 3, cells on both glass and fibrin adopt a spindle-like appearance with similar
dimensions and aspect ratios (p > 0.85). However, by 5 days after seeding, cells on fibrin
become more elongated than cells on glass, reflected by a significantly larger (p < 0.001) aspect
ratio.
4.2.2 Myofibroblast Differentiation on Fibrin Surfaces
To study differentiation of fibroblasts into the myofibroblast phenotype, HDF were seeded at 200
cells/mm 2 on fibrin surfaces with 10% fibronectin to maximize cell viability without deviating
significantly from in vivo estimates of fibrin clot composition. Less than 10% of samples seeded
in this manner experienced spontaneous cell death on the third day of culture, but very few cells
(< 5%) seeded at this density display stress fibers that stain positively for a-SMA. Of the
experimental variations listed in Table 4.1, cells seeded on fibrin and stimulated with TGF-p 1 in
absence of a biomaterial showed the most cells expressing a-SMA. A sample image is shown in
Figure 4.4.
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Figure 4.4. Cells seeded on fibrin in absence of a scaffold, 5 days post-seeding. Cells have been
stimulated with 5 ng/ml TGF-p 1 during the duration of the experiment. Red shows f-actin, blue
shows cell nuclei, and green shows a-SMA. Cell with stress fibers marked by u-SMA is denoted
with an arrow.
Although data are limited due to few cells expressing a-SMA, the results seem to indicate that
cells may be more contractile on fibrin than on glass.
4.2.3 a-SMA Expression of Fibroblasts Cultured in the Presence of Fibrin and a
Biomaterial
To investigate the effect of a biomaterial on the contractility of cells cultured in the presence of
fibrin, the in vitro experiment was conducted for all samples listed in Table 4.1. In every sample
unstimulated with TGF-l 1 and seeded at 200 cells/mm 2 , cells expressed small but detectable
amounts of a-SMA, observed in a diffuse pattern throughout the center of the cell, not as stress
fibers (Figures 4.5 and 4.6 show representative images for cells cultured in the presence of
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devices D and E, respectively). Even with TGF-p lstimulation, very few cells (< 5%) seeded at
200 cells/mm 2 display stress fibers that stain positively for a-SMA.
Figure 4.5. Cells seeded on fibrin in contact with scaffold D, 5 days post-seeding. Cells have
been stimulated with 5 ng/ml TGF-pl during the duration of the experiment. Red shows f-actin,
blue shows cell nuclei, and green shows a-SMA.
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Figure 4.6. Cells seeded on fibrin in contact with scaffold E, 5 days post-seeding. Cells have
been stimulated with 5 ng/ml TGF-pl during the duration of the experiment. Red shows f-actin,
blue shows cell nuclei, and green shows a-SMA.
The presence of a biomaterial appears to reduce cell contractility compared to that observed on
fibrin alone (Figure 4.4). No detectable difference in a-SMA expression was observed for cells
seeded on fibrin in the presence of devices D and E with or without TGF-p 1 stimulation.
4.3 Discussion
In this chapter, the effect of biomaterial properties on the contractility of fibroblasts in the
presence of fibrin and a biomaterial was studied through an in vitro experiment. In vivo, cells
that form the contractile cell capsule migrate from transected nerve stumps along the periphery
of the fibrin clot, in contact with both fibrin and the entubulation device. To create an in vitro
environment analogous to these in vivo conditions, fibroblasts were cultured between fibrin
surfaces and disks of selected biomaterials.
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This study presents preliminary results for the in vitro model. Monitoring the behavior of human
dermal fibroblasts (HDF) on fibrin and glass surfaces revealed that cells appear to spread more
extensively on fibrin compared to glass 1 day after seeding, but become more elongated than
cells on glass by 5 days post-seeding.
Interestingly, over 90% of cells seeded at low density (< 20 cells/mm 2) do not survive beyond 3
days in culture. The probability of spontaneous cell death is reduced when cells are seeded at a
higher density. One possible explanation of this finding is inadequacy in the number of binding
sites available for cells to attach. Cells require fibronectin to bind to fibrin, so if the number of
binding sites via fibronectin is inadequate and there are not enough cells to produce adequate
amounts of fibronectin, cells cannot properly attach. This explanation is supported by consistent
observations that cells cultured on fibrin surfaces without fibronectin do not survive, but the root
cause of the behavior remains unknown. Previously, it has been observed that fibroblasts detach
from two-dimensional extra-cellular protein coatings every 16-18 hours, then reattach [135]; this
behavior is extremely important for cell proliferation [157] and offers a mechanism by which
rapid cell death on lyophilized fibrin surfaces may occur. It would be very interesting to further
investigate these mechanisms in search of potential solutions.
In this thesis, cells were seeded on fibrin surfaces at a higher density to mitigate spontaneous cell
death. Although cell viability improves when cells are seeded at high density, the number of
cells that express a-SMA drastically decreases as cell density increases. Therefore, although
cells are robust when seeded at a density of 200 cells/mm 2, not enough cells expressing a-SMA
were present to make any definite conclusions regarding cell contractility in the presence of
fibrin and/or biomaterials of different properties. Qualitative observations seem to indicate more
cells expressing a-SMA on fibrin versus glass surfaces. The presence of both devices D and E
appear to downregulate a-SMA expression compared to that observed on fibrin alone. However,
no differences in a-SMA expression were observed between cells in contact with device D
compared to those in contact with device E.
In this chapter, we developed a standard assay for evaluating the effect of a biomaterial on the
behavior of contractile cells interacting with a fibrin matrix. However, many research questions
112
remain unanswered. Determining the cause of spontaneous cell death on the third day of culture
for many samples (particularly those seeded at low density) may lead to redesign of the assay for
better success with low density cell cultures. The ability to seed cells at lower density would
likely result in a higher percentage of cells expressing a-SMA, assuming that cells which
differentiate into myofibroblasts behave similarly to comeal fibroblasts [158].
Given necessary improvements, the assay developed in this thesis could be used to evaluate the
effects of biomaterial properties on contractile cell behavior by studying homologous biomaterial
libraries with varying properties other than those induced by different crosslinking methods or by
studying biomaterials that vary in a single, controlled property. It may be particularly interesting
to also study the effect of silicone on cell contractility since it is one of the standard conduit
materials in the literature and its performance against collagen conduits in vivo is well-
documented [140].
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Chapter 5: Conclusions
This thesis had three objectives: 1. to develop a mechanical model of early stage peripheral nerve
regeneration that takes into account the mechanical effect of a nerve conduit on the distribution
of compressive forces applied by cells and considers the kinetics of nerve and capsule formation
during the first two weeks of wound healing, 2. to determine the effect of nerve conduit
properties on the kinetics of nerve tissue synthesis (evaluated by monitoring the quantity of
axons and Schwann cells as a function of time and location) and capsule formation (evaluated by
monitoring the thickness of the capsule as a function of time and location), and 3. to develop an
in vitro assay that can be used to determine the effect of nerve conduit properties on a-SMA
expression by human dermal fibroblasts present at a fibrin-biomaterial interface analogous to the
entubulated post-transection environment of contractile cells in vivo.
5.1 Modeling of Early Stage Entubulated Peripheral Nerve Regeneration
The thin capsule, multi-layer capsule, and kinetic models presented in this thesis are the first
developed mechanical models that attempt to describe how biomaterials affect the wound healing
outcome after peripheral nerve injury based on mechanics and the kinetics of elementary
processes. The most detailed mechanical model presented in this thesis incorporates three
concentric cylindrical layers that model fibrin/nerve tissue, the contractile cell capsule, and the
nerve conduit. It also incorporates the kinetics of fibrin, nerve tissue, and capsule formation
based on observations in silicone conduits.
The kinetic model is useful in determining order of magnitude estimates of tissue deformation
and in investigating the parameters that most strongly affect deformations and stress magnitudes
in the compliant fibrin clot. As the deformations and stresses rise in the fibrin clot during the
early stages of wound healing, the framework available to cells that later synthesize new nerve
tissue is drastically reduced, potentially resulting in an inferior regenerate. Based on the studies
conducted in this work, the parameters most crucial in controlling the extent of fibrin
deformation appear to be contractile capsule growth rate and the relationship between nerve front
(Schwann cells, fibroblasts, endothelial cells) velocity and capsule front (contractile cells)
velocity.
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Although the kinetic model developed in this thesis offers a more complete portrayal of the
simultaneous processes that occur during the first two weeks post-transection as compared to the
Brau, thin capsule, and multi-layer capsule models, it could be improved in many ways.
Modeling the tissue, contractile capsule, and conduit using the principles of viscoelasticity
instead of simple isotopic elasticity would give rise to better approximations of material
behavior. Further studies describing the polymerization of fibrin and lateral growth of the
contractile cell capsule would provide more accurate fibrin stiffness and loading profiles for
implementation into finite element models, which would lead to more accurate fibrin
deformation and stress distribution profiles in the numerical solution. Additional investigations
into mechanisms of force generation by cells in wound healing could either justify the first order
relationship assumed here between capsule forces and capsule thickness or provide a more
realistic relationship. Finally, it would be interesting to determine the effects of cell signaling,
cytokines, conduit fillings, and other factors that can potentially affect the elementary processes
of early stage regeneration.
5.2 Effect of Nerve Conduit Material on the Elementary Processes of Early
Peripheral Nerve Regeneration
The ex vivo imaging study presented in this thesis suggests that there is an effect of material
chosen for entubulation on the kinetics of peripheral nerve regeneration during the first two
weeks post-injury. A statistically significant increase in the number of Schwann cells was
revealed as early as week 1, and by week 2 there was a statistically significant increase in both
number of axons and number of Schwann cells in a device that has resulted in a high quality
regenerate at 9 weeks post-transection based on the observations of previous investigators
(device D in Table 2.2) [2]. Further, by 2 weeks post-transection, axons and Schwann cells were
observed further into the gap entubulated by device D than the gap entubulated by device E,
suggesting faster migration speed of Schwann cells and axons in device D as well.
The same cross-sections harvested at 1 and 2 weeks post-transection approximately every 2 mm
from the proximal stump to the gap midpoint of the rat sciatic nerve suggest that nerve conduit
properties may also have a significant effect on both the radial and axial growth of the capsule
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into the gap from the proximal nerve stump. Preliminary results indicate that device D increases
axial migration speed of contractile cells, while device E causes increased radial growth of the
capsule near the proximal stump.
These observations justify the necessity of a mechanical model that incorporates the kinetic
effects of early stage nerve formation, such as the one developed in this work. Additionally, they
suggest a positive correlation between faster nerve tissue formation and slower radial growth of
the capsule in the first two weeks post-transection and long-term regenerate quality, supporting
the hypothesis that nerve formation kinetics in the early stages of wound healing may have a
significant influence on long-term regenerate quality.
Future work investigating the effect of nerve conduit properties on the elementary processes of
nerve tissue and capsule formation could involve in vivo experiments using another library of
homologous conduits with a single varying parameter or more detailed tracking of Schwann
cells, axons, endoneurial cells, and capsule thickness into the gap at more time points (possibly
by existing wide-field imaging techniques that have been used previously to image fluorescently-
stained axons in the central nervous system [152]). These would be worthwhile endeavors to
enhance understanding of how biomaterial properties affect the elementary processes of early
stage wound healing.
5.3 Effect of Biomaterials on Capsule Formation During Early Wound
Healing Based on an In Vitro Model
In this thesis, an in vitro assay was developed which can be used to study the effect of
biomaterials on capsule formation during the early stages of wound healing. This assay involves
fabrication of thin (2-3 pm), sterile fibrin surfaces with 10% fibronectin that can be used for cell
culture. PDMS is used to create wells that isolate cells on fibrin and can be used to contain a
scaffold in constant contact with seeded cells.
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Development of this assay resulted in several observations that remain unexplained. The most
interesting observation was spontaneous cell death overnight on the third day of culture. Over
the time period of assay development, this phenomenon occurred on approximately 15% of all
surfaces, consistently on the third day of culture. The probability of spontaneous cell death rose
to over 90% when cell seeding density was below 20 cells/mm 2 but was reduced when cells were
seeded at higher densities. The effect of seeding density on spontaneous cell death should be
further studied to determine the probability of cell death over a wider range of variables,
including fibrin/fibronectin composition. As discussed in Chapter 4, one possible explanation of
this finding is inadequacy in the number of binding sites available for cell attachment. It has
been observed that fibroblasts detach from two-dimensional extra-cellular protein coatings every
16-18 hours, then reattach [135], a behavior which affects cell proliferation [157] and offers a
potential mechanism for rapid cell death on lyophilized fibrin surfaces.
An improvement of this work would involve quantitative analysis of a-SMA expression by
means of Western blotting, as the experiment conducted in this thesis can only provide
qualitative observations based on immunofluorescent staining. Most a-SMA expression in cells
cultured at high density was observed in a diffuse pattern, not in the form of stress fibers.
However, various samples and even different areas of the same samples appeared to stain more
strongly for a-SMA than others. It is not known whether this observation is actually due to
higher a-SMA expression or simply an artifact of the experimental setup. To fully understand
how the presence of a biomaterial affects cell expression of a-SMA in the presence of fibrin, a
quantitative study must be performed.
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Appendix A: Protocols
A.1 Cell Splitting
(Adapted from Tzeranis)
Materials
* PBS (Gibco 14190-1440) stored at 4C, sterile
* Cell culture medium, stored at 4'C, sterile
o Human dermal fibroblasts: DMEM++ (DMEM plus 10% FBS, 1%
penicillin/streptomycin)
- DMEM, high glucose, no sodium pyruvate (Invitrogen 11965092)
- Fetal bovine serum (Invitrogen 16000036), stored at -20'C until added to DMEM.
- Penicillin/streptomycin (Invitrogen 15140148), stored at -20 0C until just before added
to DMEM
* Trypsin 0.05% with 0.02% EDTA (Gibco 25300-054), stored at 40C, sterile
* Pasteur pipettes, sterilized (VWR 14672-380).
* Serological pipettes, 5 ml, 10 ml (VWR).
* Pipettes and pipette tips, 200 p1, 1 ml.
* T25 or T75 Cell culture flasks with vented caps (BD 353108 , BD 353136).
Equipment
* Water bath
* Biological hood
* Cell incubator connected to CO 2 tanks (370C, 5% CO 2)
* Upright light microscope
* Hemocytometer
* Centrifuge
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Procedure
Preparation
1. Prepare the biological hood: switch light from "UV" to "light", wipe all surfaces with
70% ethanol.
2. Open the Pasteur pipette metal box, remove one Pasteur pipette (without touching the
others), and place the Pasteur pipette on the vacuum tube.
3. Warm PBS, trypsin/EDTA and cell medium aliquots in a water bath at 370C for 10 min.
4. Transfer the culture flask(s) to be split into the biological hood.
Detach cells
1. Aspirate the cell medium in the cell culture flasks using the Pasteur pipette connected to
the vacuum pump.
2. Use a serological pipette to add VPBS ml PBS to each flask (Table A.1). Roll gently. This
wash removes residual cell culture medium that impedes trypsin/EDTA activity.
3. Aspirate PBS using a Pasteur pipette.
4. Use a serological pipette to add Vypsin ml trypsin/EDTA to each flask (Table A. 1).
5. Incubate flasks for 5 minutes inside the cell incubator.
6. Image the flasks in the microscope to check that cells have detached from the flask and
are floating freely in the medium.
7. If cells are not detached, incubate for 5 additional minutes in the cell incubator.
8. Use a serological pipette to add Vmedneutr ml cell culture medium to each flask (Table
A. 1). This step neutralizes trypsin/EDTA action, which can kill cells if excessive.
9. Use a serological pipette to aspirate the detached cells from the flasks without creating
bubbles:
" Aspirate and wash the flask surface 8 times.
o Aspirate and respirate the cell suspension 8 times.
- Aspirate the cell suspension and place cells in 15 ml or 50 ml conical tubes.
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Table A.1. Cell culture parameters.
VPBS [ml] Vtrypsin [ml] Vmedneutr [ml] Vmedflask [ml]
T25 flasks 1.5 0.5 1 3
T75 flasks 3 1.5 3 5
Wash & count cells
1. Centrifuge conical tubes containing the cell suspension at 220xg for 5 min at 25 0C.
2. During centrifugation, prepare the flasks of the new culture passage:
a. Label the new flasks with date, cell type, passage number, and user name.
i. The "passage" number is an indicator how many times a particular cell
culture has been split. Every split increases passage number by 1.
b. Add Vmedflask cell culture medium to each flask (Table A. 1).
c. Wipe the flasks with 70% ethanol and transfer them in the cell incubator.
d. Add 10% bleach to flasks of the previous cell culture passage, incubate 20
minutes, and dispose of bleached medium in the sink and of bleached flasks as
biohazard waste.
3. When centrifugation is done, transfer the conical tubes in the biological hood, and use a
Pasteur pipette to aspirate the supernatant without disturbing the cell pellet.
4. Use a 1 ml pipette to add 1 ml PBS to each centrifuge tube, break the cell pellet, and mix
well using the same pipette tip.
5. Collect all cell suspensions (same cell type, passage number) into a single conical tube.
Add 2-5 ml more PBS. Make sure to keep record of total volume of PBS (VcelIpBs) added.
6. Mix the cell suspension well (using a 1 ml pipette) and then quickly use a 200ul pipette to
transfer a 40 pl aliquot of cell suspension into a PCR tube for cell counting.
7. Centrifuge the conical tube at 220xg for 5 min at 25 0C.
8. During centrifugation, use the 40 pl cell suspension aliquot for cell counting:
a. Clean the hemocytometer with 70% ethanol
b. Transfer 20 [tl of cell suspension into the two parts of the hemocytometer
c. Count the mean number of cells (M) in each quadrants of the hemocytometer, and
average.
d. Total number of cells Nceits in the cell suspension is:
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Nceiis = M VcellPBS ' O
e. Each T75 flask should provide 1.5-2 million fibroblasts. Each T25 flask should
provide 0.5-0.7 million fibroblasts.
9. When centrifugation is done, transfer the conical tubes in the biological hood, and use a
Pasteur pipette to aspirate the supernatant, avoid disturbing the cell pellet.
10. Use a iml pipette to transfer Ncen1s/10 6 ml cell culture medium to each pellet (e.g. if the
cell pellet contains Nceis = 1E6 cells, add 1 ml medium), and use the same pipette tip to
break the pellet. This results in a 1000 cells/ 1 cell suspension.
Create new cell culture
1. Transfer labeled flasks of the new culture from the incubator into the biological hood.
2. Use a pipette to transfer a proper amount of 1000 cells/ul cell suspension to each flask.
o The proper number of cells depends on the cell line. For fibroblasts, transport
250E3 cells to a T25 flask and 750E3 cells to a T75 flask.
3. Spray the flasks with 70% ethanol and transfer back to the incubator.
4. Aspirate 5-10 ml 10% bleach (to clean the vacuum tube) using the Pasteur pipette and
dispose.
5. Cover the vacuum tube with aluminum foil.
6. Wipe all surfaces with 70% ethanol, switch the biological hood light from "light" to
"UV", and close the sash.
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A.2 Fabrication of Thin Fibrin Surfaces
Materials
* Plasma cleaner (PDC-32G Cleaner/Sterilizer, Harrick Plasma, NY)
e 22x22mm #1.5 coverslips
e Fibrinogen (Sigma F8630)
e Thrombin (Sigma T7513)
e Fibronectin (Sigma F-4759)
* 250 mM CaCl2
e Sterile PBS (Gibco #14190-144), stored at 4'C
Equipment
* Cell incubator (37'C, 5% C0 2)
e Freeze dryer (VirTis genesis 25EL)
* Oven (Fisher IsoTemp 201, Fisher Scientific, Boston, MA, 120'C)
e Forceps (sterile)
Procedure
Prepare fibrin solution
1. Prepare solutions of fibrinogen and thrombin+5mM CaCl 2 (4 mg/ml fibrinogen and 50
U/ml thrombin solutions will make fibrin with 2 mg/ml fibrinogen and 25 U/ml thrombin
using this protocol). If desired, add 5-10% fibronectin to the fibrinogen solution.
2. Over ice, add equal volumes of fibrinogen and thrombin solution (+/- fibronectin) in a
200 pl tube.
3. Allow fibrin to polymerize in a 37'C, 5% CO 2 incubator for 30 minutes.
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Plasma treat and freeze drv thin fibrin surfaces
1. Turn on the freeze dryer and set it to reach -40'C. Place an open glass Petri dish on the
shelf.
2. Wipe coverslips to be coated with fibrin with 70% ethanol and dry completely.
3. Place the coverslips on trays in a PDC-32G plasma cleaner (18 22x22 mm coverslips can
be treated in one run of the plasma cleaner), close the door, and shut the valve.
4. Turn on the vacuum for 2 minutes (until vacuum reaches ~100 mTorr), then turn on the
plasma, starting first at low before increasing to medium, then high.
5. Keep plasma setting on high for 30-45 seconds, then decrease gradually to medium and
low before finally turning the plasma cleaner off.
6. Slowly release the vacuum to prevent coverslips from moving inside the plasma cleaner.
7. Remove coverslips from the plasma cleaner trays using forceps and store them in a
covered Petri dish.
8. Pipette 5 p.L of polymerized fibrin onto a treated coverslip within 30 minutes of plasma
cleaning treatment and use the pipette tip to spread the solution evenly over the surface of
the coverslip.
4. Repeat for all coverslips and allow the fibrin solution to air dry until the freeze dryer
equilibrates at -40'C.
5. Release any vacuum that has been created in the freeze dryer.
6. Gradually immerse fibrin-coated coverslips in liquid nitrogen individually. Immediately
after immersion, place flash-frozen fibrin-coated coverslips fibrin side up into the Petri
dish stored inside the freeze dryer.
7. When all coverslips have been immersed in liquid nitrogen and placed in the freeze dryer,
cover the Petri dish and complete the freeze dry cycle with the following settings:
a. 10 minutes at atmospheric pressure and -40'C
b. 15 minutes at 100 mTorr and -40'C
c. 600 minutes at 100 mTorr and 4'C
d. 120 minutes at 100 mTorr and 20'C
8. When the freeze dryer has equilibrated at 20'C during the final step, release the vacuum
inside the freeze dryer and remove the Petri dish.
9. Defrost the freeze dryer.
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Crosslink fibrin surfaces
1. Transfer the Petri dish into an oven under vacuum set at 120'C, and allow
dehydrothermal (DHT) crosslinking to crosslink the fibrin coverslips for 48 hours.
2. After 48 hours of DHT, remove the Petri dish from the oven and store sterile covered
fibrin surfaces at room temperature until use (see "Culturing Cells on Lyophilized Fibrin
Surfaces").
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A.3 Fabrication of PDMS
Materials
* Petri dishes (4 inch-diameter)
* PDMS polymer resin and curing agent (SYLGARD@ 184 silicone elastomer kit, Dow
Coming, MI)
" Wooden tongue depressors
" Autoclave pouches
Equipment
e Scale
e Oven (80'C)
* Scissors (sterile) or razor blade (sterile)
* Autoclave
Procedure
1. Prepare PDMS with a 10:1 by weight ratio of polymer resin and curing agent.
2. A total of 30 g PDMS will make three 4 inch diameter PDMS sheets.
3. Stir thoroughly with a tongue depressor until mixture becomes bubbly.
4. Pour 10 g PDMS into each of three 4 inch-diameter Petri dishes.
5. Place the Petri dishes under a vacuum for approximately 30 minutes or until all bubbles
have been removed. Larger air bubbles may have to be perturbed manually.
6. Release the vacuum and cure the PDMS by placing the Petri dishes in an oven set to
80'C for 2 hours.
7. Use a razor blade or sterile scissors to cut cured PDMS into sections of usable size for
cell culture on fibrin coverslips.
8. Place pre-cut PDMS into sterilization pouches and autoclave for 20 minutes. Store at
room temperature until use (see "Culturing Cells on Lyophilized Fibrin Surfaces").
125
A.4 Preparation of 0.5% Collagen-Glycosaminoglycan Suspension
(Adapted from Harley, 2006 [1, Tzeranis)
Materials
e Type I microfibrillar bovine tendon collagen (Integra LifeSciences, Inc., Plainsboro, NJ);
stored at 40C
e Distilled, deionized water
" Glacial Acetic Acid (Mallinckrodt Chemical Co., Paris, KY)
* Chondroitin 6-sulfate from shark cartilage (Cat. No. C-4384, Sigma-Aldrich Chemical
Co., St. Louis, MO); stored at 40C
Equipment
e Suspension mixer (Ultra Turrax T18 Overhead blender, IKA Works, Inc., Wilmington,
NC)
Procedure
Preparation
1. Prepare VHAc 0.05M acetic acid
2. Add 2 .9 VHAc pIl glacial acid (VHAc in ml) to VHAc ml ddH20.
3. VHAc should be at least 10% more than the total collagen suspension.
4. Cool the acetic acid at 40C for fifteen minutes.
5. Clean the mixing chamber and the dispersion element components with 0.05 M acetic
acid and wipe them with Kim-Wipes to remove all dust and any remaining CG content
from the previous run
6. Incubate the dispersing element at 4'C for 10 min inside an autoclave pouch.
Preparation of Collagen-GAG Suspension
1. Transfer Vi ml 0.05M acetic acid into a beaker of volume approximately 2Vi (Table
A.2).
2. Keep the beaker inside a bucket filled with ice and water for the remaining steps.
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3. To prepare 0.5% collagen suspension (without GAG), use V1+V2 acetic acid instead of
V1.
4. Add mconl mg microfibrillar bovine tendon collagen I to Vi ml 0.05M acetic acid.
Incubate at 40C for ten minutes so that collagen dissolves completely.
5. Assemble the suspension mixer.
6. Blend the collagen suspension at 15,000 rpm (blender setting 3.25) for tb minutes.
7. Monitor the suspension temperature. When the suspension temperature rises above 10 C,
stop blending and wait until temperature lowers.
8. Use the collagen suspension immediately or store it at 40C. If it is necessary to use the
collagen suspension without GAG, degas the suspension using the procedure described
below for the collagen-GAG suspension.
9. Prepare the GAG solution: dissolve mGAG mg chondroitin-6-sulfate in V2 ml 0.05M
acetic acid (Table A.2).
10. Use a 1 ml pipette to transfer the GAG solution drop-by-drop (8 ml/min or 133 pl/sec)
into the collagen suspension while bending at 15,000 rpm (blender setting 3.25) on ice.
11. Blend the collagen-GAG suspension tb minutes at 15,000 rpm (blender setting 3.25) on
ice.
12. Either degas and use the suspension immediately, or store at 40C.
Table A.2. Collagen-GAG suspension parameters.
Collagen-GAG mconl [mg] Vi [ml] mGAG [mg] V2 [ml] tb [min]
Suspension Volume
720 ml* 3600 600.0 320.0 120 90
100 ml 500 83.3 44.4 16.7 12.5
80 ml (1 pan) 400 66.7 35.2 13.3 10
* Harley, 2006
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Degassing & Storing Collagen-GAG Suspension
1. Transfer the suspension from the beaker into an erlemeyer flask that has at least five
times the volume of the suspension.
2. Seal the flask and transfer it to 500 Technology Square inside a bucket filled with ice (no
water in order to avoid spills).
3. Connect the erlemeyer flask to a vacuum for 2.5h on ice.
4. Transfer the flask on ice back to room 3-315.
5. Transfer the collagen suspension either into clean molds for freeze-drying, or into a
sterile bottle for storage at 4'C.
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A.5 Collagen-GAG Scaffold Fabrication: Constant Cooling Lyophilization
(Adapted from Harley, 2006 [11)
Materials
* Type I collagen-glycosaminoglycan suspension (67.25 ml/sheet)
e 5" x 5", 18 gauge 304 stainless steel pan (VirTis Inc., Gardiner, NY)
* 0.05 M acetic acid
Equipment
e Freeze dryer (VirTis genesis 25EL)
Procedure
Preparation
1. Turn on the freeze dryer.
2. Turn on the Condenser switch.
3. Turn on the Freeze and Heat switches.
4. Allow approximately 60 minutes for the freeze dryer temperature to stabilize and for the
condenser to reach a cold enough temperature to continue. After this, the "condenser"
value should lie between -14 and -20'C.
5. Clean pans with ethanol or 0.05 M acetic acid and wipe the inside with Kim-Wipes to
remove all dust and any remaining collagen-GAG from the previous run.
6. Pipet 67.25 ml of degassed collagen-GAG suspension into each pan.
7. Remove any air bubbles introduced into the suspension during the pipetting step using a
200 gl pipette tip. Drag the bubbles to the edge of the pan, allowing them to stick to the
edge. Place the pan into the freeze dryer.
8. Load the desired program by clicking Load Recipe.
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Program 2: Ramp to -40'C. Total time from start to sublimation: ~135 minutes
Mean pore size: 95.9 ± 12.3 pm
Percent porosity: 0.994
Specific surface area (S.A./Vol): 0.00748 pm-
Freezing Step Temperature, *C Time, min R/H
1 (start) 20 5 H
2 ("ramping") -40 65 R
3 ("annealing") -40 >60 H
Program 3: Ramp to -30"C. Total time from start to sublimation: -105 minutes
Mean pore size: 109.5 ±18.3 pm
Percent porosity: 0.994
Specific surface area (S.A./Vol): 0.00655 [tm'
Freezing Step Temperature, *C Time, min R/H
1 (start) 20 5 H
2 ("ramping") -30 40 R
3 ("annealing") -30 >60 H
Program 4: Ramp to -20 0C. Total time from start to sublimation: -90 minutes
Mean pore size: 121.0± 22.5 tm
Percent porosity: 0.994
Specific surface area (S.A./Vol): 0.00593 tm-1
Freezing Step Temperature, "C Time, min R/H
1 (start) 20 5 H
2 ("ramping") -20 30 R
3 ("annealing") -20 >60 H
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Program 5: Ramp to -10"C. Total time from start to sublimation: ~80 minutes
Mean pore size: 150.5 ± 32.1 pm
Percent porosity: 0.994
Specific surface area (S.A./Vol): 0.00477 pnm'
Freezing Step Temperature, "C Time, min R/H
1 (start) 20 5 H
2 ("ramping") -10 20 R
3 ("annealing") -10 >60 H
NOTE: In all cases, Step 3 should run for at least 60 minutes. Each program is followed by
a sublimation step below 300 mTorr and at 0"C for 17 hours, followed by equilibration at 300
mTorr and at 200C.
Lyophilization
1. After confirming the program, press the Start Current Cycle. The program should start
running. Leave the program to run for the specified length of time.
2. At the end of sublimation and equilibration at 20 0C, press the Cancel Current Cycle
button to cancel the program. Type "Y" in the box that appears.
3. Turn on the Vacuum Release switch.
4. Wait for the pressure to equilibrate to atmospheric pressure.
5. Remove the pan from the main chamber.
6. Turn off the Vacuum Release switch.
7. Connect the tube to the condenser to allow it to drain.
8. Turn on the Defrost switch.
9. Remove the collagen-GAG scaffold from the pan with sterile forceps.
10. Place the scaffold into an aluminum foil packet and store it in a desiccator.
11. Wash the stainless steel pan with ethanol or 0.05 M acetic acid and wipe down with Kim-
Wipes to remove any portion of the scaffold that may have torn during removal.
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A.6 Dehydrothermal Crosslinking Protocol
(Adapted from Harley, 2002 11501)
Materials
e Lyophilized type I collagen-glycosaminoglycan suspension (67.25 ml/sheet), stored in
aluminum foil packets
Equipment
0 Oven (Fisher IsoTemp 201, Fisher Scientific, Boston, MA)
Procedure
1. Leaving the aluminum foil packet open at the top, place into oven (Fisher Scientific
IsoTemp 201) at desired temperature
2. Turn on vacuum to reach a final pressure of approximately -29.7 mmHg.
3. After desired crosslinking time (typically 24-48 hours), turn off the vacuum and vent.
4. Once the vacuum has been released, open the door and immediately seal aluminum foil
packets.
5. Store sterile, crosslinked collagen sheets in a desiccator until use.
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A.7 EDAC-NHS Crosslinking of Collagen Scaffold Samples
(Adapted from Harley, 2006 [1], Tzeranis)
Materials
scaffold sheet, fabricated by freeze-drying, stored desiccated at room
temperature
* 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC, E7750, Sigma-Aldrich), stored
desiccated at -20 0C
* N-hydroxysuccinimide (NHS, #H7377,
temperature.
Sigma-Aldrich), stored desiccated at room
* Eppendorf tubes or PCR tubes
* Sterile autoclaved water
* IM Tris HCl (pH 7.4)
* 5 or 8 mm dermal biopsy punch (Miltex, 52441 or Miltex, 52443)
Equipment
* Biological hood
* Analytical balance
* Shaker
Procedure
1. Inside a sterile biological hood, cut the cylindrical scaffold samples to be crosslinked using a
5 or 8 mm dermal biopsy punch.
2. Estimate the dry mass mscaf of collagen (in mg) in each scaffold sample:
mscaf = f ' P ' Vscaf
where f is the scaffold mass volume fraction (usually 0.005 for collagen scaffold sheets, 0.05
for collagen tubes), p qkg 1 mg 3L mm3 1 , and Vscaf is the scaffold sample volume (in,Il
o e.g., for a 0.5% 8mm-diameter 3mm-thick scaffold sample, mscar = 377 pg
On the assumption that the scaffolds are entirely composed of collagen, there are 1.2 mmol
of COOH groups per gram of collagen [159].
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e Collagen
3. Determine the required EDC-NHS reaction volume Vreaction (protocol is based on the
Harley, 2006 5:2:1 EDAC:NHS:COOH recipe)
V = 410 -mscaf
where Vr is in pl and mscaf in mg.
4. Hydrate scaffolds in V/2 volume of autoclaved H20:
o Add Vr/2 volume autoclaved H20 for each scaffold sample to be crosslinked inside a
sterile eppendorf tube
o Can crosslink multiple scaffold samples per tube
o Use sterile forceps to place collagen scaffold samples on top of H20.
o Within a few minutes, the scaffold will get hydrated
5. Prepare 2x EDC-NHS solution:
o Prepare at least Vr/4 volume of 4xEDAC solution (57.6 mM):
o That EDAC at room temperature for 10 minutes
o Add 11.02 mg EDAC per 1 ml autoclaved H20. Store at 4'C until use.
o EDAC is toxic! Be careful during weighing
o Prepare at least Vr/4 volume of 4xNHS solution (22.2 mM):
o Add 2.56 mg NHS per I ml autoclaved H2 0. Store at 4'C until use
o NHS is toxic! Be careful during weighing
o Prepare 2xEDAC-NHS working solution, by mixing Vr1/4 volume of 4xEDAC
solution and Vr1/4 volume of 4xNHS solution
6. Transfer Vr/2 volume of 2xEDAC-NHS working solution into the eppendorf tube that
contains the scaffold samples hydrated in Vr/2 volume of H20.
o Mix well using a pipette
7. Incubate 1 hour at room temperature.
8. Use a pipette tip to dispose of the EDAC-NHS solution.
9. Wash the scaffolds in autoclaved water 3 times for 10 minutes each.
10. Add V volume of 50Mm Tris-HCl, pH 7.4, and mix well using a pipette.
11. Incubate 30 minutes at room temperature to quench remaining reactive sites.
12. Wash the scaffolds in final buffer 3 times for 10 minutes each.
o The final buffer depends on the downstream application. If the scaffolds are to be
used to incubate cells, final buffer could be PBS
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A.8 Culturing Cells on Lyophilized Fibrin Surfaces
Materials
" Sterile, fibrin-coated glass coverslips fabricated by freeze-drying, crosslinked by DHT,
stored inside a Petri dish at room temperature (see "Fabrication of Thin Fibrin Surfaces").
" 3mm-thick sterile sheet of porous collagen-based scaffold fabricated by freeze-drying,
crosslinked by DHT, stored desiccated inside aluminum foil in room temperature
e PDMS, autoclaved and stored in sterilization pouches (see "Fabrication of PDMS")
" 6-well polystyrene plate (BD Falcon #353046, VWR Scientific, Inc., Bridgeport, NJ)
* PBS, sterile (Gibco #14190-144), stored at 40C
e Cell culture medium, stored at 40C
0 Fibroblast culture: DMEM++ (DMEM, 10% FBS, 1% penicillin streptomycin)
- DMEM medium, high glucose, no sodium pyruvate (Invitrogen, 11965092)
- Fetal bovine serum (Invitrogen, 16000036)
- Penicillin and streptomycin (Invitrogen , 15140148)
e Biopsy punch, 5 mm diameter (Miltex, 52441) or 8 mm diameter (Miltex, 52443)
Equipment
e Biological Hood
" Forceps (sterile)
e Scissors (sterile)
" Cell incubator (370C, 5% C0 2)
Procedure
Prepare PDMS wells
1. Transfer autoclaved PDMS (see "PDMS Fabrication") inside a sterile pouch into the
biological hood.
2. Use sterile scissors to cut approximately 15 mm x 15 mm PDMS squares from larger
sheets, if necessary.
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3. Use a biopsy punch to cut 5 mm or 8 mm diameter wells in the PDMS squares.
4. Store prepared PDMS wells in the biological hood until fibrin surfaces are prepared.
Prepare fibrin surfaces
1. Transfer the Petri dish containing thin fibrin surfaces into the biological hood.
2. Place a single glass coverslip coated with fibrin into one well of a 6-well plate using
sterile forceps.
3. Press a PDMS square with a 5 mm or 8 mm diameter well onto the fibrin surface,
taking care to remove all bubbles between the PDMS and the coverslip (as these may
cause leakage of cell culture medium and subsequent dehydration and death of cells).
4. Repeat until wells have been created on all fibrin surface samples and store 6-well
plates in a cell incubator for later use.
Prepare cell suspension and add cells to fibrin surfaces
1. Detach 70-80% confluent cells from a flask, wash in PBS, and resuspend in cell
culture medium to a final concentration of 1000 cells/pL (see "Cell Splitting
Protocol").
2. Use a 10 pL pipette to place a 5 ptL drop of cell suspension (5000 cells) at the center
of a PDMS well on a fibrin surface Avoid allowing the cell suspension to come into
contact with PDMS, which will cause cells to aggregate at the edges of the well.
3. Cover the 6-well plate, wipe with 70% ethanol, and allow cells to attach to fibrin in
the cell incubator for 30 minutes.
4. After 30 minutes, fill the PDMS wells completely with cell medium.
5. If desired, use sterile forceps to place a collagen scaffold on the top of the well (see
"Collagen-GAG Scaffold Fabrication: Constant Cooling Lyophilization"). After it
becomes saturated, it will sink to the bottom of the well and come in contact with
cells attached to the fibrin surface. The "pan side" (least shiny) of the scaffold should
be facing the drop.
6. Repeat this procedure for all fibrin surfaces.
7. Cover the 6-well plate, wipe with 70% ethanol, and transfer into the cell incubator.
8. Change medium in the wells daily.
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A.9 Fluorescence Staining of Nerve Samples
(Adapted from Tzeranis)
Materials
* WGA-alexa488
e Nerve samples: 6 pm thick sections of rat sciatic nerves, embedded in OCT, stored at
-20 0C.
* Hydrophobic pen, stored at 40C
e Tris Buffered Saline with 0.05% tween20 (TBST)
* Tris Buffered Saline (TBS)
* DAKO protein block, stored at 4'C
* DAKO antibody diluent, stored at 40C
e Triton X100 (TX100)
* Primary antibodies (S100 [Abcam, ab76729], a-SMA [Sigma, A2547], NF200
[Abcam, ab72996])
* Control antibodies (mouse IgGI [Santa Cruz, sc3 877], rabbit IgG [Santa Cruz,
sc2027])
0 Secondary antibodies (Donkey anti-rabbit alexa488, Donkey anti-rabbit alexa350,
Donkey anti-mouse alexa488, Donkey anti-mouse alexa350, Donkey anti-chicken
TRITC)
e Counter-stains (DAPI, Rhodamine phalloidin [Invitrogen, R415])
* Mounting medium (Fluoro-Gel)
* #1.5 coverslips
Equipment
* Immunofluorescence microscope
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Procedure
1. Thaw samples by incubating at room temperature for 30 min.
2. Place samples inside a microscope glass holder filled with TBST and shake gently two
times for 10 min.
3. Prepare 80 pl blocking buffer per section.
o DAKO protein block, 0.3% Triton X100: 0.24 pl TXOO 80 pl DAKO protein
block.
4. Use a folded kimwipe to remove TBST around and between nerve sections.
o Add TBST if necessary to prevent drying.
5. Use a hydrophobic pen to isolate each tissue section (on the dried part of the glass).
6. Aspirate remaining TBST from the sections and add 75 pl blocking buffer per section.
7. Incubate for 60 min at room temperature.
8. During the last part of the blocking incubation prepare 60 pl primary antibody or control
antibody solution per section.
o Dilute the antibodies in DAKO antibody diluent.
o The control antibody should be from the same host and have the same antibody
isoform as the primary antibody.
o The control antibody solution should contain the same antibody density (pg/ml)
as the primary antibody solution.
9. Micro-centrifuge primary antibody solutions at 14000rpm for 40 seconds to pellet
antibody chunks.
10. Add 50 p l primary/control antibody solution per section.
o Use one tip for each group of sections that contain the same primary/control
antibody.
11. Incubate the sections with the primary/control antibody solutions overnight at 40C.
12. Aspirate the primary/control antibody solutions.
13. Wash the sections three times for 10 minutes each using 80-100 Pl TBS.
14. Apply the following steps in the dark, using a red lamp to prevent fluorophore
photobleaching.
15. During the last two washes, prepare 60 pl secondary antibody solution per section.
o Dilute the secondary antibody in DAKO antibody diluent.
o Micro-centrifuge the secondary antibody solutions at 14000rpm for 40 seconds to
pellet antibody chunks.
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16. After the last wash, add 50 pl secondary antibody solution per section.
17. Incubate the samples for 2 hours at room temperature in the dark.
18. Toward the end of the secondary antibody incubation, prepare 60 1d counter-staining
solution per section.
19. Aspirate the secondary antibody solution from each section.
20. Wash the sections two times for 10 minutes each using 80-100 p1 TBS.
21. Add 50 pl counterstain solution per section.
22. Incubate for 30 min at room temperature in the dark.
23. Aspirate the counterstain solution and dispose according to EHS regulations.
24. Wash the sections three times with 80 1tl TBS for 10 min each. Dispose of washes
according to EHS regulations.
25. During the washes, prepare coverslips.
o Wipe a #1.5 coverslip with 70% ethanol and dry thoroughly.
o Note the location of the sections with respect to the coverslip (when the coverslip
does not cover the white part of the microscope glass).
o Place a drop of mounting medium inside an eppendorf tube. Transfer 4 pl
mounting medium on the coverslip at locations corresponding to the sections.
- Avoid bubbles.
26. After the last wash, slowly place the coverslip on top of the samples without trapping
bubbles between the section and the coverslip.
27. Seal the sample and the coverslip using nail hardener.
28. Image the samples no sooner than 15 min to let the hardener solidify.
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A.10 Fluorescence Staining of Cells Cultured on Lyophilized Fibrin Surfaces
Materials
" Human dermal fibroblasts (HDF) cultured on fabricated lyophilized fibrin surfaces,
stored at 37 0 C, 5% CO 2 (cell incubator)
" Phosphate Buffered Saline (PBS), sterile (Gibco #14190-144), stored at 40C
* Counter-stains (DAPI, Rhodamine phalloidin [Invitrogen, R415])
Equipment
* Biological hood
" Chemical hood
" Cell incubator (370C, 5% C0 2)
Procedure
Prepare 4% Paraformaldehyde (PFA) in PBS
1. Weigh and transfer 800 mg paraformaldehyde (PFA) in a 50 ml container with a cap.
2. In a chemical hood, add 20 ml PBS and cover the container.
3. Stir and heat the mixture between 55'C and 65'C until the solution becomes clear.
4. Let the solution cool to room temperature.
5. Store the solution at 4'C until use.
Preparation
1. Prepare the biological hood: switch light from "UV" to "light", wipe all surfaces with
70% ethanol.
2. Open the Pasteur pipette metal box, remove one Pasteur pipette (without touching the
others), and place the Pasteur pipette on the vacuum tube.
3. Warm PBS, trypsin/EDTA and cell medium aliquots in a water bath at 370 C for 10 min.
4. Transfer the culture flask(s) to be split into the biological hood.
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Cell Fixation
1. Transfer covered Petri dish containing cells to be stained into the biological hood.
2. Remove medium from cells.
3. Wash with PBS for 5 minutes.
4. Remove PBS.
5. Pipette enough 4% PFA to cover the cells and incubate for 15 minutes at room
temperature.
6. Dispose of PFA according to EHS regulations.
7. Perform two washes (10 minutes each) with PBS, and dispose of the washes according to
EHS regulations.
Cell Staining
1. In the dark, prepare a solution of 1:100 rhodamine phalloidin and 1:5E5 DAPI in
autoclaved, distilled, and deionized water.
2. Pipette the staining solution on to the cells and incubate for 30 minutes in the cell
incubator (37'C, 5% CO 2).
3. At the end of the incubation, dispose of the staining solution according to EHS
regulations.
4. Perform two washes (10 minutes each) with PBS, and dispose of the washes according to
EHS regulations.
5. Add PBS to keep the stained cells moist, and store samples in the dark at 4'C until
imaging.
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Appendix B: MATLAB Codes
B.1 Thin and Multi-Layer Capsule Model Codes
clear all
close all
%%%USER DEFINED VARIABLES
vtis=0.25;
Etis=[50,250,500000]; %Pa
vscaf=0.01;
vmfb=0.33;
Emfb=10; %Pa
N=1; %number of myofibroblast layers
rt=0.0005; %tissue radius (m)
t=0.0005; %thickness of scaffold (m)
tm=t/100; %thickness of mfb layer (m)
mfbstress=-40; %Pa--stress resulting from ONE LAYER
c2tis=Etis/((1-2*vtis)*(l+vtis));
c2scaf=Escaf (index) / ( (1-2*vscaf) * (1+vscaf));
cmfb=Emfb/ ( (1-2*vmfb) * (1+vmfb));
%%%% Calculate integration constants by populating a matrices A and B that
%%%% represent the boundary conditions and finding the solution x to Ax=B
Btis=0;
%%%%%%%%%%%%%%%%%%P%%%%%%%%%%
%Initialize matrices A,B
A=zeros (3,3);
B=zeros (3,1);
% Displacement continuity between tissue and mfb layer 1 at the radius of
% the tissue
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A(2,1)=-rt;
A(2, 2) =rt;
A(2,3)=1/rt;
%%%% Calculate integration constants by populating a matrices A and B that
%%%% represent the boundary conditions and finding the solution x to Ax=B
Btis=O;
%Initialize matrices A,B
A=zeros((2*N+3), (2*N+3));
B=zeros((2*N+3),1);
%Begin to populate BCs
% Displacement continuity between tissue and mfb layer 1 at the radius of
% the tissue
A(N+1,1)=-rt;
A(N+1, 2) =rt;
A(N+1, 3) =1/rt;
for n=l:N
B (n, 1) =mfbstress (1);
% % % % To apply loads at outer radius of each MFB layer
if n<N
A (n, 2*n) =cmfb;
A(n,2*n+l)=cmfb*(1-2*vmfb)
A(n,2*n+2)=cmfb;
A(n,2*n+3)=cmfb* (1-2*vmfb)
elseif n==N
A(n,2*n)=cmfb;
A(n,2*n+l)=cmfb*(1-2*vmfb)
A(n,2*n+2)=c2scaf;
/ ( (rm(n) ) ) "2;
/((rm(n)) )^ 2;
/((rm(n)))^2;
A(n,2*n+3)=c2scaf*(1-2*vscaf)/(rm(n))^2;
end
end
% To apply loads at inner radius of each MFB layer
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%
%
%
%
%
%
% % % % % % % % if n==l
% % % % % % % % A(n,2*n) =c2tis;
% % % % % % % % A(n,2*n+l)=c2tis*(1-2*vtis)/(rt)^2;
% % % % % % % % A(n,2*n+2)=cmfb;
% % % % % % % % A(n,2*n+3)=cmfb*(1-2*vmfb)/(rt)^2;
% % % % % % % % elseif n==N
% % % % % % % % A (n, 2*n) =cmfb;
% % % % % % % % A(n,2*n+l)=cmfb*(1-2*vmfb)/((rm(n-1)))^2;
% % % % % % % % A(n,2*n+2)=cmfb;
% % % % % % % % A(n,2*n+3)=cmfb*(1-2*vmfb)/(rm(n-1))^2;
%- % % % 6 % %6 % end
% % % % % % % To apply loads at capsule radius midpoint
if n>1
A (n, 2*n) =2*cmfb;
A(n,2*n+l)=2*cmfb*(1-2*vmfb)/((rm(n)+rm(n-1))/(2))^2;
elseif n==1
A (n, 2*n) =2*cmfb;
A(n,2*n+l)=2*cmfb*(1-2*vmfb)/((rm(n)+rt)/(2))^2;
end
end
% radial stress continuity at rt (due to bonding)
A(N+2, 1) =-c2tis;
A (N+2, 2) =cmfb;
A(N+2,3)=cmfb*(-1+2*vmfb)/(rt)^2;
% Other displacement continuities
if N==1
A(N+3,2*N)=rm(N);
A(N+3,2*N+1)=l/rm(N);
A(N+3,2*N+2)=-rm(N);
A(N+3,2*N+3)=-1/rm (N);
elseif N>1
for o=l:N
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A(N+2+o,2*o)=rm(o);
A(N+2+o,2*o+l)=l/rm(o);
A(N+2+o,2*o+2)=-rm(o);
A(N+2+o,2*o+3)=-l/rm(o);
end
end
% Radial stress at the outermost radius is 0 (free surface)
A((2*N+3), (2*N+3-1))=c2scaf;
A((2*N+3), (2*N+3))=c2scaf*(2*vscaf - 1)/(rt+N*tm+t)^2;
Solve for the constants
x=linsolve(A,B)
%%%%%%%%%%%%%%%%
%%Calculate and plot stresses in the tissue portion
Rt=[0:.00001:rt];
rtnd=Rt/rt;
utis=x(l)*rtnd; %nondimensionalized radius
sigrrtis=(c2tis*(x(1))+c2tis*(2*vtis-1)*((Btis)./Rt.^2));
sigtttis=(c2tis*(x(1))+c2tis*(1-2*vtis)*((Btis)./Rt.^2));
sigzztis=(2*vtis* (x(1))*c2tis);
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B.2 Stiffness and Loading Profile Generation Code
clear all
close all
% variables include:
% cellmig, Emin, Emax, p1layer, Vmfb, Vnf, N, td, capsuletau, stiffnesstau
timesteps=28;
Emin=50; %Pa
Emax=250; %Pa
N=1; %number of layers
td=6; %number of timesteps until nerve and capsule front cells begin to
migrate
capsuletau=4;
stiffnesstau=4;
vnervecells=2.5; %mm/wk
cellmig=vnervecells/((timesteps)/2); %mm/timestep
vmfb=4; %mm/wk
mfbmig=vmfb/((timesteps)/2); %mm/timestep
pllayer=-23.121; %equivalent radial pressure to apply in ADINA-this must be
%recalculated for any changes in mechanical properties!
%Initialize matrices
stiffness=Emin*ones(timesteps,1);
ax=zeros(timesteps,1);
zn=zeros(timesteps,1);
zm=zeros(timesteps,1);
index=l;
z=linspace(0,cellmig*(timesteps-td),28);
mfbmig=vmfb/((timesteps)/2); %mm/timestep
for k=l:length(z)
pressure(k)=N*pllayer*(l-exp(-z(k)*(l/cellmig-1/mfbmig)/capsuletau));
stiffness(k)=(Emax-Emin)*(1-exp(-z(k)*(1/cellmig)/stiffnesstau))+Emin;
end
stiffpoly=polyfit(z,stiffness',4);
fit=polyfit(z,pressure,4);
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B.3 ADINA Commands Generator
%After running loading and stiffness profile generation code:
sx_4=stiff_poly(1);
sx_3=stiff poly(2);
sx_2=stiff poly(3);
sxl=stiffpoly(4);
sxO=stiff-poly(5);
fx_4=fit (1) ;
fx_3=fit (2) ;
fx_2=fit (3) ;
fxl=fit(4);
fx_0=f it (5);
n=1;
minlayer=l;
x=1;
load=201;
stiffness=l;
loading=l;
snum=33;
num=l;
cellmig=(vnervecells/(timesteps/2));
mfbmig=4/((timesteps)/2);
%% Stiffness
%define stiffnesses
for x=1:100
z=7.5/100;
if x==l
fprintf('MATERIAL E NA=%d E=%f
NU=%d\n',stiffness,sx_4*(x*z)^4+sx_3*(x*z)^3+sx_2*(x*z)^2+sx_1*x*z+sx_0,
0.25)
fprintf('EGROUP THREEDS N=%d DI=large M=%d\n',stiffness,stiffness)
stiffness=stiffness+3;
else
if sx_4*(x*z)^4+sx_3*(x*z)^3+sx_2*(x*z)^2+sx_1*x*z+sx_0<Emin
fprintf('MATERIAL E NA=%d E=%d NU=%d\n',stiffness,Emin, 0.25)
fprintf('EGROUP THREEDS N=-d DI=large M=%d\n',stiffness,stiffness)
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stiffness=stiffness+1;
elseif sx_4*(x*z)^4+sx_3*(x*z)^3+sx_2*(x*z)^2+sxl*x*z+sx_0>Emax
fprintf('MATERIAL E NA=%d E=%d NU=%d\n',stiffness,Emax, 0.25)
fprintf('EGROUP THREEDS N=%d DI=large M=%d\n',stiffness,stiffness)
stiffness=stiffness+1;
elseif x*z>cellmig*22
fprintf('MATERIAL E NA=%d E=%d NU=%d\n',stiffness,Emax, 0.25)
fprintf('EGROUP THREEDS N=%d DI=large M=%d\n',stiffness,stiffness)
stiffness=stiffness+l;
else
fprintf('MATERIAL E NA=%,d E=%f
NU=%d\n',stiffness,sx_4*(x*z)^4+sx_3*(x*z)^3+sx_2*(x*z)^2+sxl*x*z+sx_0,
0.25)
fprintf('EGROUP THREEDS N=%d DI=large M=%d\n',stiffness,stiffness)
stiffness=stiffness+1;
end
end
end
%apply stiffnesses
egroup=l;
volstartl=506;
volstart2=606;
for n=l:100
if egroup==l
fprintf('GVO NA=%d NO=27 G=%d\n',volstartl,egroup)
fprintf('GVO NA=%d NO=27 G=%d\n',volstart2,egroup)
egroup=egroup+3;
volstartl=volstartl-l;
volstart2=volstart2-1;
else
fprintf('GVO NA=%d NO=27 G=%d\n',volstartl,egroup)
fprintf('GVO NA=%d NO=27 G=%d\n',volstart2,egroup)
egroup=egroup+l;
volstartl=volstartl-l;
volstart2=volstart2-1;
end
end
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fprintf('GVO NA=%d NO=27 G=%d\n',607,101)
%% Loading
%define loads
for x=1:100
z=7.5/100;
if z*x<cellmig*(timesteps-td)
fprintf('LOAD PR N=%d
M=%f\n',load, (fx_4*(x*z)^4+fx_3*(x*z)^3+fx_2*(x*z)^2+fx_1*x*z+fx0))
fprintf('LOAD PR N=%d M=%f\n',load-l,-
(fx_4*(x*z)^4+fx_3*(x*z)^3+fx_2*(x*z)^2+fx_1*x*z+fx_0))
load=load-2;
elseif z*x>cellmig*(timesteps-td)
fprintf('LOAD PR N=%d M=%f\n',load,0)
fprintf('LOAD PR N=%d M=%f\n',load-1,0)
load=load-2;
end
end
%apply loads
if (snum==33)
fprintf('APPLY-LOAD BODY=0\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+l,snum+3)
snum=snum+20;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=0\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
5)
snum=snum+12;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE''
''SURFACE''
%d\n',num,loading,snum)
%d\n',num+l,loading+l,snum-
''SURFACE'' %d\n',num,loading,snum)
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fprintf('%d ''PRESSURE'' %d ''SURFACE''
%d\n',num+1,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d ''SURFACE''
fprintf('%d ''PRESSURE'' %d ''SURFACE''
%d\n',num+l,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d ''SURFACE''
fprintf('%d ''PRESSURE'' %d ''SURFACE''
%d\n',num+l,loading+l,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d ''SURFACE''
fprintf('%d ''PRESSURE'' %d ''SURFACE''
%d\n',num+1,loading+l,snum+7)
snum=snum+46;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d ''SURFACE''
fprintf('%d ''PRESSURE'' %d ''SURFACE''
%d\n',num+1,loading+l,snum+3)
snum=snum+16;
num=num+l;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d ''SURFACE''
fprintf('%d ''PRESSURE'' %d ''SURFACE''
%d\n',num+l,loading+l,snum+7)
snum=snum+16;
%d\n',num,loading,snum)
%d\n',num,loading,snum)
%d\n',num,loading,snum)
%d\n',num,loading,snum)
%d\n',num,loading,snum)
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num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=0\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+1,loading+l,snum+7)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=Q\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+1,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%,d ''PRESSURE'' %d
%d\n',num+l,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=0\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=Q\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+1,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
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fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+l,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+l,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+l,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=0\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+l,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+l,snum+3)
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
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snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+1,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=\n')
fprintf('%d ''PRESSURE'' %id
fprintf('%d ''PRESSURE'' %d
'd\n',num+1,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
d\n',num+1,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+1,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=Q\n')
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE''
''SURFACE''
%d\n',num,loading,snum)
%d\n',num+l,loading,snum+5)
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
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fprintf('%d ''PRESSURE'' % d
fprintf('%d ''PRESSURE'' %d
%d\n',num+1,loading+l,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+l,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+l,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+1,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+l,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=0\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+l,snum+3)
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
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snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+1,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+1,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=0\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+1,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+1,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=\n')
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE''
''SURFACE''
%d\n',num,loading,snum)
%d\n',num+l,loading,snum+5)
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
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fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+1,loading+l,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+l,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+1,snum+7)
snum=snum+16;
num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
snum=snum+16;
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE''
''SURFACE''
%d\n',num,loading,snum)
%d\n',num+l,loading,snum+5)
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num=num+2;
loading=loading+2;
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+l,snum+7)
snum=snum+16;
num=num+2;
loading=loading+2;
while snum<1648
fprintf('APPLY-LOAD BODY=O\n')
fprintf('%d ''PRESSURE'' %d
fprintf('%d ''PRESSURE'' %d
%d\n',num+l,loading+1,snum+3)
snum=snum+16;
num=num+2;
loading=loading+2;
end
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
''SURFACE'' %d\n',num,loading,snum)
''SURFACE''
end
157
Appendix C: Nerve Formation Study Images
Device D Device E
1 week 1 week
0.100 mm 0.090 MM
1100 pm
Device D Device E
1 week 1 week
1.830 mm 1.790 mm
Device D Device E
2 weeks 2 weeks
0.410 mm 0.240 mm
10011pm
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Device D Device E
2 weeks 2 weeks
1.710 mm 1.790 mm
1I pc Jm
Device D Device D
2 weeks 2 weeks
3.960 mm 4.140 mm
Device D Device D
1 week 1 week
0.120 mm 1.630 mm
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Device E Device E
1 week1 week
0.050 mm .1.790 mmi
100 pm 
--
Device D Device E
2 weeks 2 weeks
1.850 mm 0.220 mm
- -- -- - ----- ---
Device E Device E
2 weeks 2 weeks
1.610 mm 1.610 mm
Figure C.1. Fluorescent images of cross-sections obtained from transected rat sciatic nerves.
Red denotes axons, green denotes Schwann cells, and blue denotes cell nuclei. Scale bars = 100
prm. Captions denote device, time, and axial location (z).
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AppendixUPRAli D: Cotat- Cas I Fomto Stud ImagesIU4
Device D Device D
1 week 1 week
0.100 mm 0.120 mm
Device D Device D
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Figure D.1. Fluorescent images of cross-sections obtained from transected rat sciatic nerves.
Red denotes f-actin, green denotes a-SMA, and blue denotes cell nuclei. Scale bars = 100 pm.
Captions denote device, time, and axial location (z).
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